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Breast cancer is a prevalent disease.  Metastatic disease accounts for the 
majority of deaths from breast cancer, as patients with distant metastatic disease 
have a much worse prognosis than those with localized disease. In order to 
better understand why some breast cancers metastasize and others do not, it is 
critical to identify and elucidate the determinants of breast cancer progression. 
Post-transcriptional control of gene expression plays a central role in modulating 
transcriptional output. The interactions between messenger RNA cis-regulatory 
elements and trans-factors control coordinated gene expression states. Post-
transcriptional regulatory programs that enhance metastatic capacity are selected 
for during cancer progression. In this study, the RNA binding protein Muscleblind-
like 1 (MBNL1) is identified as a novel suppressor of breast cancer metastasis. 
MBNL1 loss-of-function contributes to the pathogenesis of myotonic dystrophy, a 
human genetic disease, but has no reported role in tumorigenesis or cancer 
progression. In this study, MBNL1 is identified as a suppressor of breast cancer 
metastasis. MBNL1 was found to suppress metastasis of human breast cancer 
cells in a xenograft mouse model. Additionally, MBNL1 transcript levels are 
significantly correlated with metastasis-free survival of breast cancer patients. 
MBNL1 depletion was also found to enhance the invasion and trans-endothelial 
migration capacity of breast cancer cells. Identification of endogenous MBNL1 
protein-RNA interactions in breast cancer cells was carried out using HITS-CLIP. 
Transcriptome-wide analysis of MBNL1-dependent transcript stability and 
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MBNL1 HITS-CLIP data revealed that globally, transcripts directly bound by 
MBNL1 are stabilized by MBNL1. Two transcripts, DBNL and TACC1, were 
identified as transcripts that were bound by MBNL1 and also destabilized upon 
MBNL1 depletion. Both DBNL and TACC1, when overexpressed in breast cancer 
cells depleted of MBNL1, were found to reverse the pro-invasive and metastatic 
colonization phenotypes observed upon MBNL1 depletion. Therefore, DBNL and 
TACC1 were identified as modulators of the metastasis suppressive effect of 
MBNL1 in breast cancer. 
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CHAPTER 1: INTRODUCTION 
1. Breast cancer incidence, classification and clinical outcomes
Breast cancer is a common disease. Worldwide, there were an estimated 
1,671,000 new cases diagnosed and 522,000 deaths from breast cancer in 2012 
(Ferlay et al. 2012). In the United States, breast cancer is the most commonly 
diagnosed cancer. There will be an estimated 231,840 new breast cancer cases 
diagnosed and an estimated 40,290 deaths from breast cancer in 2015 (Table 
1.1). The lifetime risk of being diagnosed with breast cancer for a woman in the 
US is 12.3% (Howlader et al. 2015). 
Table 1.1 Incidence of common cancers in the United States for 2015 
Clinically, breast cancer can be classified by stage, grade, hormone 
receptor/HER2 status, and gene expression signature. Stage is defined by the 
size of the primary tumor and the degree to which it has spread to other sites in 
the body. The most commonly used staging system is called TNM (Tumor, 
regional lymph Node, Metastasis). This system assesses primary tumor size, 
degree of regional lymph node involvement and presence of cancer metastasis to 
distant organs in order to determine the cancer stage. Stages range from I to IV. 
Stage I breast cancers are small, have not detectably spread to regional lymph 
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nodes and have not metastasized, and stage IV cancers are those that have 
metastasized to distant organs. Stages II and III have intermediate levels of 
cancer size and spread (Sobin et al. 2010). Grade refers to the appearance of 
the primary tumor tissue and assesses how similar to normal breast tissue the 
tumor tissue appears. In the commonly used Nottingham grading system, each of 
the following factors contributes to the final assigned tumor grade: 1) The percent 
of the tumor tissue retaining normal milk duct structures. 2) The size and shape 
of the nucleus in the cancer cells. 3) The number of actively dividing cells. 
Hormone receptor/HER2 status refers to the expression of the estrogen receptor 
(ER), progesterone receptor (PR) and of the erb-b2 receptor tyrosine kinase 2 
(ERBB2, also known as HER2/neu) by breast cancer cells. The expression of 
ER, PR and HER2 is typically assessed by immunohistochemistry, and the 
cancer is then designated as being positive or negative for expression of each of 
these factors. The expression of these factors are important for deciding the 
treatment of a breast cancer, as the effectiveness of drugs commonly used to 
treat breast cancer is largely determined by cancer cell ER, PR and HER2 
expression. Breast cancers can also be categorized by their gene expression 
signature, also known as their intrinsic molecular subtype. Transcriptomic 
profiling of large sets of breast cancers has shown that breast cancers can also 
be divided into groups based on gene expression signatures (Bertucci et al. 
2000; Perou et al. 2000; Sorlie et al. 2001; Sorlie et al. 2003). The molecular 
subtypes of breast cancer based on gene expression profiling have been 
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identified as luminal A, luminal B, HER2-enriched, basal-like, normal-like and 
claudin-low, the last two of which are rare. The luminal and basal subgroups are 
so named because their patterns of gene expression are similar to that of normal 
breast luminal and basal tissues. Classification of breast cancers by gene 
expression subtype, in addition to classification by stage, grade and 
receptor/HER2 status, can add information that is useful for prognosis and 
treatment (Kittaneh et al. 2013). Each of these criteria for classifying breast 
cancer is correlated with survival outcomes, but the stage and receptor status are 
currently the primary determinants of which therapies are used for treatment. 
However, gene expression signature information is increasingly being used to 
develop and test new targeted therapies (Eroles et al. 2012). 
Depending on how it is classified using the systems described above, a 
breast cancer may be treated with surgery, radiation and non-specific cytotoxic 
chemotherapies or anti-angiogenic therapies. However, a primary consideration 
for breast cancer treatment is the receptor status of the cancer, as cancers that 
are ER/PR positive, and/or HER2 positive are treated differently from triple 
negative/basal-like cancers. This is because specific targeted therapies exist for 
hormone receptor positive and HER2 positive breast cancers, and these 
treatments confer a survival advantage over treatment with non-specific 
therapies. There is a lack of targeted therapies for triple negative/basal-like 
breast cancers, as these cancers do not express the factors that are targeted by 
these specific drugs. The established treatment for hormone receptor positive 
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breast cancers is administration of drugs aimed at reducing estrogen signaling, 
thereby reducing tumor growth. These drugs include tamoxifen, a small molecule 
that binds to ER and inhibits estrogen signaling in breast tissue. In post-
menopausal women, aromatase inhibitors, including the small molecules 
anastrozole, exemestane and letrozole, are used to inhibit the actions of 
aromatase. The enzymatic activity of aromatase converts androgens into 
estrogen, and anti-aromatase therapy reduces systemic estrogen levels (Miller et 
al. 2014). Additionally, in pre-menopausal women, drugs can be used to 
suppress ovarian estrogen production in order to reduce systemic estrogen 
levels, although the effectiveness of this therapy in addition to tamoxifen therapy 
is not dramatic (Francis et al. 2015). The established therapy for HER2 positive 
breast cancers is trastuzaumab (Herceptin), an antibody directed against the 
extracellular domain of HER2. Trastuzaumab is effective in improving the survival 
of patients with HER2 expressing breast cancers (Piccart-Gebhart et al. 2005; 
Smith et al. 2007). However, breast cancers that have metastasized to distant 
organs remain difficult to treat, and women with breast cancer that has not 
spread from the primary site, or has spread regionally have a much higher 5-year 
survival rate compared to those who have cancer that has spread to distant 
organs (Figure 1.1A). Therefore, the majority of deaths from breast cancer are 
due to metastatic disease. 
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Figure 1.1 Breast cancer survival and metastatic progression 
(A) The 5-year survival rate of breast cancer patients in the United States, 
divided by level of spread of the cancer. (B) Illustration depicting the metastatic 
cascade.  
2. Cancer metastasis
From the above data, it is clear that the survival rate of breast cancer 
patients is dependent on the extent of cancer progression (Figure 1.1A). Because 
of this, it is important to understand the mechanisms by which cancer cells can 
successfully spread through the body and colonize distant organs, a process 
called metastasis. In this process, a cancer cell from the primary tumor moves 
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away from the primary tumor and into the surrounding tissue, intravasates into 
blood vessels, survives in circulation, extravasates out of blood vessels, and 
successfully survives and proliferates in a secondary organ (Chiang and 
Massague 2008) (Figure 1.1B). It is unlikely that a cancer cell from the primary 
tumor has the capacity to carry out all of these steps. Indeed, very few cancer 
cells from a primary tumor make it through all of the steps of the metastatic 
process. In animal models of metastasis, less than 0.01% of cancer cells in 
circulation result in macroscopic metastases (Chambers et al. 2002; Luzzi et al. 
1998). In addition to the qualities intrinsic to the cancer cell, both the 
microenvironment of the primary tumor and the microenvironment of the distal 
organ to which the cancer has metastasized play roles in modulating the 
likelihood of metastasis (Joyce and Pollard 2009). Therefore, because of the 
complex nature and clinical importance of metastasis, it is of great interest to 
identify molecules that contribute to this process. 
The first step of metastasis is cancer cell movement into blood vessels, a 
process called intravasation. Cancer cells may intravasate into vessels that are in 
direct contact with the tumor, or the cancer cell may first invade into the 
surrounding tissue and then intravasate into blood vessels. Cancer cell invasion 
can be promoted by local environmental stresses such as hypoxia, pH level and 
nutrient deprivation as well as the presence of various stromal cell types and the 
composition of the extracellular matrix (Chang and Erler 2014; Quail and Joyce 
2013). Cancer cells invade by moving through the extracellular matrix and normal 
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tissue that surrounds the primary tumor. These cancer cells can then intravasate 
into systemic circulation by moving through the layers of endothelial cells that 
comprise the blood vessel walls. Normally, endothelial cells act as a barrier to the 
movement of cells in to or out of the bloodstream, and therefore cancer cell 
movement across the endothelial cell layer is an aberrant occurrence. Cancer 
cells may intravasate through active and passive mechanisms. Tumor 
vasculature is abnormal, with leaky endothelial cell junctions and abnormal 
coverage by pericytes, features that allow for easier cancer cell intravasation 
(Dudley 2012; Xian et al. 2006). Cancer cells may also actively intravasate into 
vessels through either paracellular (movement through the junctions between 
endothelial cells), or transcellular (movement directly through the body of an 
endothelial cell) mechanisms. Many molecules that enhance invasion generally 
also enhance intravasation. Molecules expressed by breast cancer cells that are 
important for paracellular intravasation include N-WASP, which reorganizes the 
actin cytoskeleton by promoting invadopodia formation, and also enhances 
invasion and intravasation (Gligorijevic et al. 2012). Increased cancer cell 
expression of the matrix metalloproteinase MT4-MMP disrupts blood vessel 
integrity in the tumor environment, which allows for increased cancer cell 
intravasation (Chabottaux et al. 2009). Another metalloproteinase, ADAM12, is 
expressed in breast cancer tumor vasculature but not in the vasculature of 
normal breast tissue. The ectodomain shedding of endothelial cell vascular 
endothelial cadherin and of the angiopoietin 1 receptor TIE2 is mediated by 
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ADAM12, and could play a role in promoting cancer cell intravasation by 
disrupting endothelial cell junctions (Frohlich et al. 2013). Microenvirnomental 
factors can also affect intravasation: macrophages can enhance breast cancer 
cell intravasation by inducing cancer cell expression of Mena (an epidermal 
growth factor-responsive cell migration protein) through colony-stimulating factor-
1 receptor signaling (Keirsse et al. 2014). Transcellular intravasation is another 
method breast cancer cells can use to move into vessels, and a role for 
endothelial cell myosin light chain kinase has been demonstrated in this process 
(Khuon et al. 2010). Once successfully intravasated, cancer cells in circulation 
encounter and must survive multiple stresses, including the mechanical shear 
stress of the bloodstream, detachment from the ECM, and destruction by immune 
cells. 
Cancer cells then move out of circulation in a process called 
extravasation. During extravasation, cancer cell must again traverse the 
endothelial layer of blood vessels. The first step of extravasation is the adhesion 
of cancer cells to the endothelial cells of a blood vessel. This adhesion can occur 
after cancer cell arrest in capillaries due to size constraints, but can also involve 
cancer cell rolling on the vessel wall before firm adhesion (Geng et al. 2012; 
Kienast et al. 2010; Stoletov et al. 2010). Adhesion involves a large number of 
factors on both the cancer and endothelial cells. Initial attachment can occur 
through the interactions of cancer cell expressed N-cadherin, Sialyl Lewis A 
and/or CD44 with endothelial cell expressed N-cadherin and/or E-selectin. 
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Stabilization of cancer cell-endothelial cell interaction further depends on 
integrins, CD44 and/or Mucin 1 (Reymond et al. 2013). The cancer cell then 
migrates through the endothelial cell layer and into the surrounding tissue. Once 
the cancer cell has extravasated and is located in a distant organ, the 
environment of that organ and the intrinsic programing of the cancer cell both 
contribute to the suppression or promotion of cancer cell survival, proliferation, 
and ultimately formation of metastatic nodules in that distal organ. 
3. Post-transcriptional regulation of gene expression
For metastasis to occur, cancer cells must acquire cellular phenotypes 
that enable their migration into distant organs, where their subsequent survival 
and proliferation lead to end-organ failure. The enhanced invasiveness and 
migratory capacity necessary for metastasis can be generated through the 
coordinated expression of specific gene sets. Post-transcriptional regulation of 
gene expression is a method of doing this, and refers to processes that affect the 
expression of a messenger RNA (mRNA) after transcription. The post-
transcriptional control of mRNA expression is determined by interactions between 
regulatory cis-elements and trans-factors. Therefore, regulated modifications to 
cis-elements and interacting trans-factors determine the identity, localization and 
expression of a transcript. These processes include alternative splicing, 
alternative polyadenylation site selection, RNA editing, post-transcriptional 
nucleotide modification, and non-templated polyadenylation of the 3’ end of a 
mRNA (Li and Mason 2014; Liu et al. 2014; Norbury 2013). Alterations to 
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regulatory trans-factors can also affect post-transcriptional gene expression. The 
major types of trans-factors are RNA binding proteins and microRNAs, both of 
which carry out their regulatory roles through direct interactions with transcripts. 
Importantly, a single trans-factor can interact with and regulate the expression of 
multiple transcripts, thereby coordinating the expression of gene sets. 
Pre-mRNA alternative splicing and alternative polyadenylation site 
selection 
Pre-mRNA alternative splicing is a major method of transcriptome 
diversification. Although there are approximately 20,000 genes in the human 
genome, analysis of high-throughput RNA sequencing data has revealed that 
from 95-100% of human genes express alternatively spliced transcript variants 
(Pan et al. 2008; Wang et al. 2008). Interestingly, the amount of alternatively 
spliced transcripts increases with increasing organism complexity, and therefore 
the prevalence of alternative splicing in humans is thought to be necessary for 
diversifying the human proteome (Nilsen and Graveley 2010). Pre-mRNA 
alternative splicing is the process by which specific exons and introns are actively 
included or excluded from a transcript. Four major types of alternative splicing 
exist: exon inclusion, exon exclusion, mutual exon exclusion, and intron retention. 
Alternative splicing adds a regulatory layer to the basal splicing of all intron-
containing transcripts. The basic mechanism of splicing, where introns are 
removed and exons are joined together, is controlled by cis-elements in the pre-
mRNA. The conserved elements that are recognized by the spliceosome are 
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exon-intron junctions at the 5’ and 3’ ends of introns, the branch point sequence, 
located upstream of the 3’ splice site, and the polypyrimidine tract, which is 
located between the branch point sequence and the 3’ splice site. The 5’ splice 
site has a conserved GU dinucleotide and the 3’ splice site has a conserved AG 
dinucleotide. These elements are then bound in a defined order by the small 
nuclear ribonucleoprotein particles (snRNPs) U1, U2, U4/U6, and U5, which are 
central components of the spliceosome. The spliceosome is a large RNA-protein 
complex that catalyzes the removal of introns and joining of exons (Lee and Rio 
2015). In eukaryotes, exon definition is the major mechanism used by the basal 
splicing machinery. 
Alternative splicing is directed by cis-regulatory sequence elements and 
trans-factors. These regulatory elements are divided into four types: exonic 
splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing 
enhancers (ISEs), and intronic splicing silencers (ISSs). The best-studied classes 
of proteins that bind to these regulatory elements and influence exon choice are 
the ubiquitously expressed members of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family (Huelga et al. 2012), and proteins in the serine-
arginine rich (SR) protein family (Anko 2014). Another class of proteins that play 
roles in regulating alternative splicing are those that exhibit tissue-specific 
expression patterns and are involved in tissue differentiation. These include 
proteins from the NOVA (neuro-oncological ventral antigen)(Ule et al 2003; 
Zhang et al. 2010), RBFOX (Fox RNA-binding)(Weyn-Vanhentenryck et al. 2014; 
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Yeo et al. 2009; Zhang et al. 2008), CELF (CUG binding, Elav-like), and MBNL 
(Muscleblind-like) (Kalsotra et al. 2008; Ladd et al. 2001; Wang et al. 2012, 
Wang et al. 2015) families. These proteins control alternative splicing by binding 
in the upstream intron, downstream intron or in the regulated exon itself to control 
exon inclusion or skipping. Some of these factors act to recruit spliceosome 
machinery, while others act to block the actions of the spliceosome. These 
regulatory factors have also been shown to antagonize each other’s functions 
(Zhu et al. 2001). It is thought that the developmental stage and tissue-specific 
expression patterns of these factors dictate their activity. 
Although deadenylation and decapping accounts for bulk mRNA turnover, 
cis-elements and trans-factors allow for the modulation of transcript stability. Cis-
elements that regulate mRNA decay are commonly found in 3’UTRs. Many such 
elements have been identified, and are usually defined by sequence. However, 
cis-elements defined by structure rather than sequence have been identified as 
modulators of mRNA decay (Goodarzi et al. 2012). Both sequence-specific and 
structural elements interact with trans-factors, which then can affect the stability 
of the transcript through recruitment or inhibition of mRNA decay machinery. 
In addition to alternative splicing, pre-mRNAs are subject to alternative 
cleavage and polyadenylation (APA). APA produces transcripts with different 3’ 
ends, which can affect post-transcriptional gene regulation. APA is a prevalent 
mode of regulation, as approximately 70% of human transcripts have alternative 
poly(A) containing products as assessed by RNA sequencing methods (Derti et 
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al. 2012). The location of many regulatory elements, 3’UTRs are enriched in sites 
recognized and bound by trans-factors. These interactions can control the 
expression of that transcript. Therefore, shortening of a 3’UTR through APA can 
allow escape from regulation by specific trans-factors. This type of dysregulation 
has been observed in cancers (Mayr and Bartel 2009). In a subset of breast 
cancers, among transcripts with significantly different 3’UTR lengths, shorter 
3’UTRs were associated with shorter overall patient survival (Lembo et al. 2012). 
The control of the length of the poly(A) tail is another important method the 
cell uses to regulate stability and maintain steady-state levels of transcripts. 
Normally, poly(A) tails of 100-250 nucleotides are added to the 3’ end of each 
mRNA by the actions of poly(A) polymerase (PARP) and nuclear poly(A) binding 
protein (PABPN1). The presence of a poly(A) tail allows a transcript to be 
exported to the cytoplasm and engage with the translation machinery. Once in 
the cytoplasm, the length of a transcript’s poly(A) tail is then controlled by the 
opposing actions of deadenylases and adenylases. Generally, the PAN2/3 
complex (poly(A) nuclease 2/3) is the initial factor that trims the poly(A) tail of an 
mRNA, and its activity is stimulated by PABP (poly(A) binding protein). Further 
deadenylation is carried out by the CCR4-NOT complex, which can be inhibited 
or stimulated by the binding of transcript-specific RBPs. Once a transcript has 
been deadenylated to a certain point, RNA degradation occurs (Norbury 2013). 
Molecular mechanisms of mRNA degradation 
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In eukaryotic cells, a combination of factors dictate the stability of 
messenger RNAs (mRNAs). Ribonucleases control mRNA degradation through 
defined pathways and trans-acting factors and cis-acting elements control the 
rate of mRNA decay. Two critical cis-acting determinants of mRNA stability are 
incorporated co-transcriptionally: the 7-methyl-guanosine cap (m7G) which is 
added to the 5’ end of the transcript, and the poly(A) tail which is added to the 3’ 
end of the transcript. These two additions protect the transcript from immediate 
destruction by exonucleases, and their removal is crucial to normal turnover of 
mRNAs (Yamashita et al. 2005). Transcripts are constantly subjected to the 
actions of ribonucleases so as to maintain steady-state levels of mRNA in the 
cell. Transcripts can be further subject to regulated decay, both by cis-elements 
in their sequence and in response to various stimuli that regulate the level of 
trans-acting factors such as RBPs and miRNAs. 
Messenger RNAs are degraded by the enzymatic actions of 
ribonucleases, and these RNA degradation enzymes carry out their actions in a 
specific order. Here, a general overview of the major factors in these pathways in 
eukaryotic cells is given. The primary pathway of mRNA decay is the 
deadenylation-dependent pathway. In this pathway, the first step of mRNA 
degradation is removal of the poly(A) tail. This requires the action of 
deadenylases, which are 3’-5’ exoribonucleases with a high preference for a 
poly(A) substrate. Deadenylases and poly(A) polymerases dynamically control 
poly(A) tail length in the cytoplasm, and poly(A) tail length is a major determinant 
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of mRNA stability. Generally, the poly(A) tail of a transcript is bound by PABP 
(poly(A) binding protein) in the cytoplasm, and PABP interacts with eIF4G, a 
component of the eIF4F complex which binds the m7G cap at the 5’ end of the 
transcript. This interaction promotes the recruitment of the translation initiation 
complex as well as protects the transcript from degradation. Once deadenylases 
have shortened the poly(A) tail below a threshold length, PABP no longer 
interacts with the tail and the transcript is left unprotected from further actions of 
ribonucleases (Kim et al. 2006; Tharun and Parker 2001; Wilusz et al. 2001). The 
major deadenylase containing complexes that are active in metazoans are 
CCR4-CAF1-NOT, PAN2-PAN3 and PARN (Yan 2014). After removal of the 
poly(A) tail by the actions of a deadenylase complex, the remaining RNA can be 
degraded in either a 3’-5’ or 5’-3’ direction. 3’-5’ degradation occurs through the 
action of the exosome, a large multi-subunit complex with exonuclease activity 
(Houseley and Tollervey 2009). The m7G cap is then removed by DcpS 
(scavenger decapping enzyme). Messenger RNA can also be degraded in the 5’-
3’ direction after deadenylation. The first step in this process is removal of the 
m7G cap by the decapping complex, which requires the enzymatic action of 
DCP2 (van Dijk et al. 2002; Wang et al. 2002). The decapping complex also 
contains proteins that enhance decapping. In metazoans, these cofactors are 
DCP1, EDC3, EDC4, PAT1B, DDX6, and the LSM1-7 complex. These factors are 
not all required for decapping of all mRNAs, but can act in a transcript specific 
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manner (Arribas-Layton et al. 2013; Fenger-Gron et al. 2005, Ling et al. 2011). 
After decapping, the remaining RNA is degraded 5’-3’ by the exonuclease XRN1. 
Messenger RNA may also be degraded in a deadenylation-independent 
manner. However, this pathway is thought to play a very minor role in bulk mRNA 
decay in eukaryotic cells. The existence of this pathway in yeast has been 
demonstrated by studying the regulated decay of the RPS28B transcript. 
Initiation of this pathway requires the recruitment of the decapping complex 
component EDC3 to the transcript, which in turn recruits the decapping enzyme 
DCP2. After removal of the m7G cap, the RNA is degraded 5’-3’ by XRN1 (Badis 
et al. 2004). 
An additional type of mRNA decay utilizes endoribonucleases. This 
method of mRNA degradation differs from the pathways described above 
because removal of the poly(A) tail or the 5’ cap is not necessary for initiation of 
decay. Instead, endonucleases act on a capped, polyadenylated mRNA and 
cleave it. The resulting RNA pieces are then destroyed by the actions of the 
exoribonucleases XRN1 and the exosome. Instances of endoribonuclease- 
mediated mRNA decay in metazoans have been reported, but have not been 
heavily studied. Generally, these endonucleases have highly specific transcript 
targets, their action is activated by external stimuli, their actions can be localized, 
and they cleave at specific sequences. This is in contrast to the deadenylation 
and decapping that facilitates constitutive bulk mRNA turnover. The best studied 
of these endonucleases is PMR1, which was discovered in Xenopus extracts as 
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the endonuclease responsible for deadenylation independent decay of the 
albumin transcript in response to estrogen (Yang and Schoenberg 2004). In 
human cells, the PMR1 endonuclease is associated with polysomes, and 
localization of PMR1 to the leading edge of MCF7 breast cancer cells enhances 
cell motility in a scratch assay (Gu et al. 2012). Other proteins that have 
demonstrated endonuclease activity on specific mRNA substrates in metazoans 
are IRE1/ERN1 (endoplasmic reticulum to nucleus signaling 1), ZC3H12A (zinc 
finger CCCH-type containing 12A), SMG6 (SMG6 nonsense mediated mRNA 
decay factor), and APE1 (apurinic/apyrimidinic DNA endonuclease 
1)(Schoenberg 2011). SMG6 acts in the nonsense mediated decay pathway 
(Eberle et al. 2009), and therefore typically acts as a quality control factor rather 
than a regulator of the decay of specific mRNAs in response to stimulus. 
 mRNA stability regulatory pathways 
Transcripts that do not contain open reading frames (ORFs) are subject to 
active degradation by the cell to ensure the production of functional proteins. The 
recognition of transcripts without ORFs occurs through multiple mechanisms, 
depending on the problem with the transcript. Together, these are referred to as 
surveillance pathways. These are 1) nonsense mediated decay (NMD), which 
occurs when an mRNA has a premature termination codon (Kervestin and 
Jacobson 2012). 2) nonstop mediated decay (NSD), which happens when an 
mRNA does not contain an in-frame termination codon (Frischmeyer et al. 2002), 
and 3) No-go decay (NGD), which takes place when ribosomes stall at the 5’ end 
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of an mRNA (Doma and Parker 2006). These pathways of decay are triggered by 
problems in the processing or sequence of the transcript. Interestingly, NMD can 
also participate in the regulated decay of transcripts in a process called 
alternative splicing coupled NMD (AS-NMD). AS-NMD acts through selective 
degradation of mis-spliced mRNAs. Types of alternative splicing that trigger NMD 
are retention of a premature termination codon-containing exon or intron, splicing 
that leads to an elongated 3’UTR, and splicing that results in the presence of an 
upstream open-reading frame (Sibley et al. 2014). Alternative splicing can also 
lead to intron retention. In addition to triggering NMD in the cytoplasm, this can 
lead to a block on the export of a transcript to the cytoplasm, and thereby induce 
transcript degradation by the nuclear exosome (Ge and Porse 2013). 
Cytoplasmic RNA granules and mRNA stability 
The subcellular localization of a transcript also contributes to its stability. 
Processing bodies (P-bodies) and stress granules are two major types of 
cytoplasmic RNA granules that are sites of regulated mRNA decay and storage. 
Stress granules form in response to various stresses. These stress stimuli 
include oxidative stress, hypoxia, amino acid starvation, endoplasmic reticulum 
stress, heat shock, UV irradiation and viral infection. These different stimuli each 
induce the activity of specific kinases that then phosphorylate eIF2-alpha 
(eukaryotic initiation factor 2) (Kedersha et al. 1999). This phosphorylation event 
halts translation initiation, but does not affect actively elongating ribosomes. 
Stress granules contain translation initiation factors, 40S ribosomal subunits and 
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mRNAs bound to the translation pre-initiation machinery. A large number of other 
RBPs have also been found in stress granules, and the specific composition of a 
given stress granule is dependent on the identity of the cell and the type of 
stress. Another characteristic of mRNAs in stress granules is that they retain their 
poly(A) tails and remain in a closed loop formation with the cap complex 
(Anderson and Kedersha 2008). Components of stress granules disperse once 
the stress is removed, and translation of the mRNAs can resume. Stress granule 
formation may play a role in cancer progression. In a mouse xenograft model of 
osteosarcoma metastasis to the lung, depletion of the stress granule nucleating 
factor G3BP1 reduced both number of stress granules per cancer cell and 
reduced the number of metastatic nodules in the lung (Somasekharan et al. 
2015). Although this is a correlative finding, it is consistent with stress granule 
formation promoting metastasis. 
A second major type of cytoplasmic RNA granule is processing bodies, 
which have distinct components from stress granules. However, P-bodies and 
stress granules also have many overlapping components and functions, and 
these protein components, as well as RNA transcripts, can move dynamically 
between the two granule types (Kedersha et al. 2005). P-body components 
include mRNA degradation, mRNA surveillance and miRNA-mediated gene 
silencing factors. The decapping enzyme DCP2 is a characteristic component of 
these foci. Unlike stress granules, P-bodies are constitutively present. Although 
they contain mRNA decay machinery, and are thought to be the sites of mRNA 
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decay, the presence of P-bodies is not required for global or specialized RNA 
decay to occur (Eulalio et al. 2007; Stoecklin et al. 2006). 
4. RNA binding proteins, tumorigenesis and cancer progression
RNA interacting proteins are abundant, with ~550 mRNA-interacting 
proteins common to both HeLa and HEK293 cells (Baltz et al. 2012; Castello et 
al. 2012). Through their interactions with RNA, these proteins mediate a variety 
of regulatory processes that have wide-ranging downstream effects in 
development, homeostasis and pathological processes. The majority of RNA 
binding proteins bind multiple RNA transcripts and/or other RNA molecules and 
in doing so can impact the regulation of those RNAs. Given their ability to 
coordinately regulate sets of transcripts, proteins belonging to this group have the 
potential to confer attributes that affect the metastatic potential of cancer cells. 
Indeed, recent studies have noted such effects on breast cancer progression for 
a variety of RNA-binding proteins. The metastasis modulating effects of these 
RNA-binding proteins have been shown to be generated through different post-
transcriptional regulatory steps, including direct modulation of transcript stability 
by TARBP2 (Goodarzi et al. 2014) and RBM47 (Vanharanta et al. 2014), as well 
as regulation of alternative splicing patterns by HNRNPM (Xu et al. 2014). The 
role of RNA binding proteins in breast cancer tumorigenesis, in contrast to cancer 
progression, has been more heavily studied. Among the best-studied RBPs in 
breast tumorigenesis are ELAVL1 (embryonic lethal abnormal vision-like 1, also 
known as HuR) and ZFP36 (zinc finger protein 36, also known as TTP). Both are 
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AU rich element (ARE) -binding proteins, and ELAVL1 is commonly upregulated 
in breast cancer, while ZFP36 is commonly downregulated (Sanduja et al. 2010; 
Abdelmohsen and Gorospe 2010). 
5. Muscleblind-like family: Identification and structure
One RNA binding protein that has been implicated in human genetic 
disease and in the regulation of alternative splicing is Muscleblind-like 1 
(MBNL1). The Muscleblind-like family of proteins is present in organisms ranging 
from worms to humans. Muscleblind-like proteins do not exist in bacteria, fungi or 
plants, and only occur in metazoans. Invertebrates have one muscleblind-like 
gene, while the majority of vertebrates have three muscleblind-like genes 
(Pascual et al. 2006). Members of this family contain highly conserved cysteine-
cysteine-cysteine-histidine (CCCH) zinc finger domains with which they bind 
RNA. These CCCH zinc finger domains are common, and are found in over 1000 
proteins. CCCH zinc finger domains bind specific sequence motifs in RNA. 
Consistent with this observation, SELEX studies have determined that MBNL1 
binds the RNA motif YGCY (Goers et al. 2010), while CLIP-seq studies have 
identified an enrichment of UGC and GCU containing 4mers in MBNL1-bound 
sites in mouse myoblasts (Wang et al. 2012). Crystal structures of the MBNL1 
CCCH zinc finger domains, both while bound to RNA with the sequence 
CGCUGU, and while not bound to RNA, have been solved (Teplova and Patel 
2008). These structures show that the two pairs of zinc fingers have a symmetric 
fold where the two zinc fingers in each pair are connected by a linker that orients 
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their RNA binding surfaces away from each other, making the RNA fold into an 
antiparallel form. This structure as well as other in vitro biochemical binding data 
(Goers et al. 2010) suggests a model where the zinc fingers of MBNL1 interact 
with the 5’-GC steps in RNA that folds into hairpin structures with bulged and 
unpaired uridines. 
MBNL proteins in development 
Work on a Drosophila melanogaster mutant led to the first characterization 
of a muscleblind family member, with the observation that in Drosophila, 
muscleblind is required for normal development of photoreceptor cells as well as 
for normal muscle differentiation and attachment (Begemann et al. 1997; Artero 
et al. 1998). In mammals, the three members of the Muscleblind-like family are 
MBNL1, MBNL2 and MBNL3, and all contain four tandem CCCH zinc finger 
domains. These highly similar proteins exhibit tissue-specific expression 
patterns. MBNL1 is the most highly expressed member of the family, and is 
detected in adult skeletal muscle, heart, brain, intestine, kidney, liver, lung and 
placenta. Mice with genetic knockout of MBNL1 develop muscle weakness, 
cataracts and cardiac pathology (Dixon et al. 2015; Kanadia et al. 2003). Loss of 
MBNL1 function results in a shift to fetal and embryonic stem cell-like transcript 
splicing patterns, and also impairs erythroid terminal differentiation (Cheng et al. 
2014; Han et al. 2013; Lin et al. 2006). MBNL2, like MBNL1, is detectable in most 
adult tissues, with the highest expression in brain, and has decreased expression 
in heart and skeletal muscle compared to MBNL1. Mice null for MBNL2 do not 
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display abnormal muscle development, but they exhibit sleep disturbances, 
impaired learning and are prone to seizures (Charizanis et al. 2012). Of the three 
MBNL members, MBNL3 has the lowest expression levels. MBNL3 is primarily 
expressed during embryonic development, but is also detectable in adult lung, 
spleen and testis. Interestingly MBNL3 expression is decreased in myoblasts 
when they are induced to differentiate, and overexpression of MBNL3 
suppresses myoblast differentiation (Kanadia et al. 2003; Lee et al. 2007; 
Squillace et al. 2002). These expression patterns and developmental phenotypes 
are consistent with a model where MBNL1 and MBNL2 promote normal tissue 
differentiation while MBNL3 acts as a suppressor of differentiation. Together, 
these MBNL1-dependent developmental phenotypes and the lack of MBNL 
orthologs in single cell organisms suggest that MBNL family proteins function 
primarily to ensure correct differentiation of tissues. 
MBNL molecular mechanisms 
MBNL1 has a well-characterized role in the regulation of pre-mRNA 
splicing. The first pre-mRNAs found to have MBNL1-dependent alternative 
splicing were identified because these transcripts had been found to have altered 
splice forms in myotonic dystrophy, a disease in which MBNL1 has a pathogenic 
role, as discussed in the next section. These first identified alternatively spliced 
genes were TNNT2 (cardiac troponin T type 2) and INSR (insulin receptor) (Ho et 
al. 2004). In a study examining the mechanism of MBNL1-regulated alternative 
splicing of the TNNT2 pre-mRNA, MBNL1 was found to bind to a stem-loop 
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structure in the polypyrimidine tract of the intron upstream of the alternative exon 
in TNNT2 pre-mRNA. MBNL1 binding was found to inhibit the formation of the 
spliceosome complex by modulating the local RNA structure, which then 
interfered with U2AF2 binding and led to exon skipping (Warf et al. 2009). More 
recently, genome-wide sequencing and computational analyses have found 
many more MBNL family protein dependent splicing events (Charizanis et al. 
2012; Du et al. 2010; Wang et al. 2012). Mechanistically, MBNL protein splicing 
function is dependent on where the protein binds relative to the alternative exon. 
MBNL1 and MBNL2 binding on the alternative exon or within the upstream intron 
usually leads to skipping of the alternative exon (Charizanis et al. 2012; Du et al. 
2010; Wang et al. 2012). MBNL1 binding to the downstream intron promotes 
retention of the alternative exon. In addition to the cis-acting sequences in a 
transcript, trans-acting factors can also influence the binding of MBNL1 to RNA. 
A study has shown that the DEAD-box RNA helicase DDX5 promotes MBNL1 
binding to the stem-loop regulatory element in the TNNT2 pre-mRNA (Laurent et 
al. 2012). Interestingly, another DEAD-box helicase, DDX6, has been found to 
interact with and unwind CUG repeat expansion RNA hairpins, leading to a 
decrease of MBNL1 binding to these RNA structures (Pettersson et al. 2014). 
MBNL1 co-immunoprecipitates with several proteins in human myoblasts, 
including hnRNP H,H2, H3, F, A2/B1, K, L, DDX5, DDX17 and DHX9, and these 
may act in concert with MBNL1 to affect RNA splicing (Paul et al. 2011). More 
definitively, CLIP-seq analysis of MBNL and CELF1 determined that these 
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proteins have opposing effects on the splicing of a large set of alternative exons 
(Wang et al. 2015). 
MBNL1 has also been found to developmentally regulate alternative 
poly(A) site selection in mouse embryonic fibroblasts through directly binding to 
3’UTRs (Batra et al. 2014). CLIP-seq analysis of MBNL1 and MBNL2 in mouse 
myoblasts in combination with cellular fractionation and transcriptomic profiling 
led to a proposed model wherein MBNL1 binding to 3’UTRs promotes localization 
and cytoskeletal trafficking of transcripts, which then promotes secretion of their 
protein products (Wang et al. 2012). Another study analyzed CLIP-seq of MBNL1 
in mouse myoblasts and proposed that MBNL1 binding destabilizes transcripts 
(Masuda et al. 2012). Clearly, MBNL1 has multiple mechanisms through which it 
post-transcriptionally regulates gene expression. 
6. MBNL and human genetic diseases
Myotonic dystrophy 
To date, most studies on MBNL family proteins have investigated the 
mechanism through which they contribute to the pathology of myotonic 
dystrophy, a human genetic disease. Myotonic dystrophy is the most common 
muscular dystrophy that affects adults, with an estimated global incidence of 1 
case per 8,000 people. People affected with this disease exhibit muscle 
weakness and atrophy, cardiac conduction defects, cataracts, diabetes, male 
frontal balding, various behavioral changes and hypersomnia (Udd and Krahe 
2012). Two forms of the disease exist, myotonic dystrophy type 1 (MD1) and 
26 
myotonic dystrophy type 2 (MD2), which are classified according to the genic 
location of the causative mutation. In both types, the causative mutation is a 
nucleotide repeat expansion in a non-coding region of a gene. In type 1, this is a 
(CTG)n repeat expansion in the 3’UTR of the DMPK (Dystrophia Myotonica 
Protein Kinase) gene (Aslanidis et al. 1992; Brook et al. 1992; Harley et al. 1992; 
Mahadevan et al. 1992). In type 2 disease this is a (CCTG)n repeat expansion in 
the first intron of the CNBP (CCHC-type zinc finger, Nucleic acid Binding Protein) 
gene (Liquori et al. 2001). 
The mechanism through which these repeat expansions lead to the 
pathology associated with the disease has been intensely studied. The prevailing 
model for how these repeat expansions cause the pathologic features of 
myotonic dystrophy is an RNA gain-of-function mechanism (Figure 1.2A). In this 
model, transcripts containing these repeat expansions accumulate in the nucleus, 
where they bind proteins, effectively sequestering these proteins and preventing 
their normal actions in the cell. Several lines of evidence point to this RNA gain-
of-function model being a major contributor to myotonic dystrophy pathogenesis. 
Mice null for DMPK exhibit late onset myopathy, but do not display myotonia and 
cataracts, two phenotypes characteristic of myotonic dystrophy (Reddy et al. 
1996). Also, although SIX5 (Sine oculis-related homeo box 5), the gene located 
immediately downstream of DMPK, has reduced expression levels in MD1 due to 
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Figure 1.2. RNA gain-of-function model for myotonic dystrophy 1 pathogenesis 
Illustration depicting the toxic gain-of function RNA model for the pathogenesis of 
myotonic dystrophy 1. An expansion of the number of CTG trinucleotide repeats 
in the 3’UTR of the DMPK gene, which normally contains 5-37 CTG repeats, 
leads to the accumulation of DMPK transcripts with CUG trinucleotide repeat 
expansions. This RNA then has a gain-of-function by binding and sequestering 
MBNL1, preventing the normal functions of MBNL1 in the cell. 
the expanded (CTG)n repeat in the 3’UTR of DMPK (Klesert et al. 1997), mice 
null or heterozygous for SIX5 develop cataracts but no abnormal muscle 
phenotype (Klesert et al. 2000; Sarkar et al. 2000), again, suggesting that SIX5 
levels are not sufficient to phenocopy the symptoms of myotonic dystrophy. The 
evidence in favor of the RNA gain-of-function model includes a characteristic 
accumulation of nuclear foci in muscle samples from individuals affected with 
myotonic dystrophy, and that these nuclear foci contain the expanded repeat 
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transcripts (Liquori et al. 2001; Mankodi et al. 2001; Taneja et al. 1995). The 
identification of MBNL proteins as (CUG)n repeat binding proteins (Miller et al. 
2000) and the discovery that MBNL proteins colocalize with the (CUG)n 
expanded repeat-containing RNA in nuclear foci further supports this model 
(Fardaei et al. 2001; Mankodi et al. 2001). Another critical finding in support of 
this model was that MBNL1 null mice recapitulate many of the phenotypes 
characteristic of myotonic dystrophy, including myotonia and cataract 
development (Kanadia et al. 2003). 
It is thought that the pathogenesis of myotonic dystrophy is caused by the 
dysregulation of the alternative splicing of a set of transcripts normally regulated 
by MBNL proteins. In favor of this spliceopathy model, a study compared global 
splice forms in MBNL1 null mice with those in a mouse model of MD1, where 
animals were engineered to express a transgene consisting of 250 CUG repeats 
in the human skeletal muscle actin gene 3’UTR (Mankodi et al. 2000). This 
showed a ~80% overlap in splice forms in the two mice (Du et al. 2010). Taken 
together, the evidence supports a model for myotonic dystrophy pathogenesis 
where expanded repeats in non-coding genic regions result in the accumulation 
of “toxic” repeat-containing RNAs that bind MBNL proteins and prevent them 
from carrying out their usual functions. 
Spinocerebellar ataxia 8 
Although their role in myotonic dystrophy is the most heavily studied, there 
is evidence that MBNL1 functions in the pathogenesis of another human genetic 
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disease, spinocerebellar ataxia 8 (SCA8). SCA8 is a slowly progressing 
neurodegenerative disease that affects the cerebellum. The causative SCA8 
mutation is a CAG CTG repeat expansion in the overlapping genes ATXN8OS 
and ATXN8, which are located on opposite DNA strands (Koob et al. 1999). This 
expansion results in an expanded run of glutamines in the protein product of 
ATXN8, and a CUG trinucleotide repeat expansion in the non-coding ATXN8OS 
transcript (Moseley et al. 2006). In tissue samples from both individuals affected 
with SCA8 and from mice engineered to express the ATXN8OS transcript 
containing expanded CUG repeats, ATXN8OS transcripts with expanded CUG 
repeats were observed in ribonuclear inclusions. Interestingly, MBNL1 was also 
localized in these inclusions in specifically the molecular layer interneurons and 
deep cerebellar nuclei (Daughters et al. 2009). 
Fragile X-associated tremor/ataxia syndrome 
MBNL1 has been found in nuclear inclusions specific to Fragile X-
associated tremor/ataxia syndrome (FXTAS), which is another late onset 
neurodegenerative disease. FXTAS affects the cerebellum and white matter of 
the brain. In males, there is a 1 in 3,000 lifetime risk of developing FXTAS, 
although the incidence of the causative mutation is higher (Jacquemont et al. 
2004). The causative mutation is an expanded CGG repeat in the 5’UTR of the 
FMR1 gene. When this trinucleotide is repeated more than 200 times, it leads to 
loss of FMR1 expression and to fragile X syndrome, a more severe condition 
than FXTAS. However, when the CGG trinucleotide is repeated 55 to 200 times 
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(normal repeat number is 5 to 40), it can lead to FXTAS. This intermediate 
number of CGG repeats leads to an increase in the level of FMR1 mRNA, 
although there are normal to reduced levels of the FMR1 protein (Hagerman et 
al. 2001; Hagerman and Hagerman 2015). A characteristic of FXTAS is the 
presence of ubiquitin positive nuclear inclusions in neurons and astrocytes. In 
samples from FXTAS patients, these inclusions were isolated and mass 
spectrometry analysis found, among other proteins, the presence of MBNL1 and 
the RNA binding protein HNRNPA2/B1 (Iwahashi et al. 2006). In FXTAS patient 
brain samples these repeat expansion containing FMR1 transcripts co-localized 
with the RNA binding proteins SAM68, HNRNPG and MBNL1 in nuclear foci. 
However, in this study MBNL1 retained some ability to regulate the splicing of 
some of its targets (Sellier et al. 2010). Therefore, although the role of MBNL1 in 
myotonic dystrophy has been the most extensively studied, MBNL1 may also 
play a role in other human genetic diseases. 
CHAPTER 2. MBNL1 and Breast Cancer Progression 
1. Identification of MBNL1 as a suppressor of breast cancer progression
The effect of MBNL1 on breast cancer metastasis was originally examined 
because MBNL1 was a candidate miR-335 target transcript. MiR-335 has been 
identified as a suppressor of breast cancer metastasis (Tavazoie et al. 2008). 
The MBNL1 transcript has a miR-335 complementary site in its 3’UTR, however, 
overexpression of miR-335 in breast cancer cells did not modulate the level of 
MBNL1 protein (Figure 2.1A). Therefore, the seed sequence complementarity of 
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miR-335 to the MBNL1 transcript is not sufficient to repress MBNL1 expression in 
these cells. Although MBNL1 levels were unaffected by miR-335 overexpression 
in breast cancer cells, the effect of MBNL1 on breast cancer metastasis was 
tested. To assay the effect of MBNL1, a xenograft mouse model was used. In this 
assay, RNAi-mediated depletion of MBNL1 using two independent short hairpin 
RNAs (shRNAs) robustly increased the metastatic colonization capacity of MDA-
231 human breast cancer cells in tail-vein metastatic colonization assays (Figure 
2.1B). Moreover, depletion of MBNL1 also significantly enhanced (~15-fold) 
metastatic colonization by highly metastatic LM2 cells, which is an in vivo 
selected sub-population of the MDA-231 cell line (Minn et al. 2005) (Figure 2.1C). 
To test if the effect of MBNL1 on metastasis was cell line specific, the effect of 
MBNL1 knockdown on the metastatic capacity of CN34 cells was tested. The 
CN34 cell line is an independent and minimally passaged human breast cancer 
cell line (Tavazoie et al. 2008). Again, MBNL1 knockdown in this independent cell 
line significantly increased (~100-fold) lung colonization by the CN34 breast 
cancer cells (Figure 2.2A). These findings reveal that endogenous MBNL1 can 
act as a suppressor of breast cancer metastatic colonization. 
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Figure 2.1 MBNL1 identification and effect on metastatic lung colonization 
(A) Schematic depicting the miR-355 complementary site in the 3’UTR of the 
MBNL1 transcript. Western blot for MBNL1 in whole cell lysate from LM2 breast 
cancer cells overexpressing miR-335. Tubulin was used as a loading control. (B) 
1 x 105 MDA-231 cells expressing either of two independent shRNAs targeting 
MBNL1 or a control shRNA were intravenously injected into NOD-Scid mice. 
Lung colonization was assessed by bioluminescence imaging and histology at 
indicated timepoints. Representative H&E-stained lungs shown correspond to 
day 83 post-injection. N=10-11. (C) 2 x 104 LM2 cells expressing an shRNA 
targeting MBNL1 or a control shRNA were intravenously injected into NOD-Scid 
mice and lung colonization was monitored by bioluminescence imaging. 
Representative H&E and vimentin stained lungs correspond to day 64 post-
injection. N=5.  
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As injection of cancer cells into venous circulation primarily tests their capacity to 
colonize the lung, the impact of MBNL1 depletion on systemic metastasis to 
multiple organs was tested next. This was accomplished through intra-cardiac 
injection of cancer cells into the arterial systemic circulation of immunodeficient 
mice, which allows the cancer cells to pass through many organs before going 
through the lungs. This assay revealed a significant increase in the colonization 
of multiple distal organs, including brain, lung, and bone, by MBNL1 depleted 
cells relative to control cells (Figure 2.2C). This was interesting as these organs, 
as well as the liver, are the preferred sites of metastatic colonization of human 
breast cancers (Lee 1983). The effect of MBNL1 overexpression on lung 
metastatic colonization was also assayed. Overexpression of MBNL1 in highly 
metastatic LM2 cells significantly decreased their lung colonization capacity 
(Figure 2.2B). Together, these experiments show that MBNL1 is a robust 
suppressor of breast cancer metastasis to multiple distal organs. 
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Figure 2.2 MBNL1 suppresses breast cancer metastatic lung colonization 
(A) 7.5 x 104 CN34 cells expressing either an shRNA targeting MBNL1 or a 
control shRNA were intravenously injected into NOD-Scid mice and lung 
colonization was monitored by bioluminescence imaging. Representative 
vimentin stained lungs shown correspond to day 78 post-injection. N=6. (B)1 x 
105 LM2 cells stably expressing exogenous MBNL1 or a control vector were 
injected intravenously into NOD-Scid mice, lung colonization was monitored by 
bioluminescence imaging. Representative H&E and vimentin stained lungs 
shown correspond to day 37 post-injection N=10. (C) After intracardiac injection 
into athymic nude mice of 5 × 104 MDA-231 cells expressing a control hairpin or
an shRNA targeting MBNL1, systemic metastasis was monitored over time by 
bioluminescence imaging. N=10. Bioluminescence signal quantification and 
gross bone histology corresponding to bone metastasis by 5 × 105 MDA control







2. Expression and clinical correlation of MBNL in breast cancer
To test if an association exists between MBNL transcript levels and clinical 
outcome in breast cancer patients, clinical data and microarray analysis of 
primary tumors from breast cancer patients were analyzed. This analysis 
revealed that there was a significant correlation between reduced MBNL1 
transcript levels in tumors and elevated metastatic relapse rates (Figure 2.3B). 
Furthermore, breast cancer metastases expressed significantly lower levels of 
MBNL1 transcript relative to primary tumors (Figure 2.3A). However, there was 
no significant correlation between MBNL2 or MBNL3 transcript levels and distant 
metastasis free survival (Figure 2.3 C,D) (Gyorffy et al. 2010). Together, these 
data reveal a clinical association between MBNL1 expression and metastasis-
free survival in breast cancer patients. The two other human MBNL proteins, 
MBNL2 and MBNL3 do have high sequence similarity to MBNL1. However, 
MBNL1 is the most abundant MBNL transcript in breast cancer tumors, as 
assessed by RNA sequencing data from The Cancer Genome Atlas (TCGA) 
collection (Figure 2.3E). Therefore, it is reasonable that MBNL1 might play the 
dominant role in mediating MBNL family protein effects on breast cancer 
progression. Furthermore, in the cell lines used in this study, MBNL1 depletion by 
RNAi did not downregulate MBNL2 transcript levels (Figure 2.3F), therefore 
MBNL1 depletion alone is sufficient for the effects observed on metastasis 
suppression. 
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Figure 2.3 Expression and clinical correlation of MBNL in breast cancer 
(A) Dot-plot representation of MBNL1 expression in a set of 117 primary breast 
cancers and 36 distal metastases from previously published datasets. Cancer 
samples were transcriptomically profiled using a common platform, and 
normalized to allow for intra and inter-cohort comparisons. N=153. (B-D) Kaplan-
Meier survival curves depicting probability of distant metastasis free survival 
(DMFS) for breast cancer patients with tumors expressing high (red) or low 
(black) levels of each indicated MBNL family member transcript. High and low 
expression levels of each transcript were determined by dividing at the median. 
N=1609. P-value is based on the Mantel-Cox log-rank test. (E) MBNL family RNA 
levels (RPKM) in a set of breast tumors from RNA sequencing data (TCGA). 
N=1098. (F) Relative MBNL1 and MBNL2 transcript levels in MDA-231 shCTRL 
and shMBNL1 cells as assessed by qRT-PCR. HPRT1 was used as an 
endogenous control. P-values based on a two-way Student’s t-test. Data are 
shown as mean ±SEM . 
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3. Effect of MBNL1 on metastasis-associated cellular phenotypes
Next, to define the cellular phenotypes altered in cells depleted of MBNL1, 
assays for a variety of metastasis-associated phenotypes were carried out. To 
test if cell proliferation was a major contributor to the enhanced metastatic 
colonization observed upon MBNL1 depletion, cell count assays were carried out. 
The viable number of cells was counted at five days post plating. ShRNA-
mediated knockdown of MBNL1 did not enhance in vitro cell proliferation. 
Instead, MBNL1 depletion reduced the number of cells in vitro (Figure 2.4A). 
Furthermore, MDA-231 cells depleted of MBNL1 did not exhibit enhanced 
primary tumor growth rates in vivo (Figure 2.4B). Therefore, the enhanced in vivo 
metastasis phenotype exhibited by MBNL1 depleted cells is unlikely to be caused 
by increased proliferation or growth rates. 
To identify potential phenotypes exhibited by MBNL1 depleted cells that could 
enhance metastatic activity, the ability of breast cancer cells depleted of MBNL1 
to invade through matrigel was analyzed. This transwell matrigel invasion assay 
is a commonly used model of cancer cell invasion through the basement 
membrane. The major components of matrigel are laminin, entactin and collagen 
IV, all major structural proteins of the basement membrane (Hughes et al. 2010). 
Invasion through matrigel was significantly enhanced in cells depleted of MBNL1 
relative to control cells in both MDA-231 and CN34 breast cancer cell populations 
(Figure 2.4E,G).  Furthermore, this increase in invasiveness was abrogated upon 
stable overexpression of MBNL1 in cells depleted of MBNL1 (Figure 2.4F). 
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Another phenotype required for efficient metastasis to organs such as lung or 
brain, which contain endothelial barriers, is enhanced trans-endothelial migration 
capacity (Reymond et al. 2013). To assay this, a monolayer of human umbilical 
vein endothelial cells (HUVECs) was formed on a transwell insert, and cancer 
cells were seeded on top of the HUVEC monolayer. The number of cancer cells 
migrating through the HUVEC monolayer was then quantified. This assay found 
that cancer cells depleted of MBNL1 displayed enhanced trans-endothelial 
migration capacity relative to control cells (Figure 2.4D).  Importantly, MBNL1 
depletion did not enhance general migratory capacity of cancer cells in the 
absence of matrigel or endothelial cells as a barrier (Figure 2.4C). These results 
reveal that MBNL1 impedes both the invasion and trans-endothelial migration 
capacity of MDA-231 breast cancer cells, and suggests that these processes, 
fundamental to metastatic progression, contribute to the in vivo metastasis 
suppressive role of MBNL1. 
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Figure 2.4 Effect of MBNL1 on cell proliferation, migration, transwell invasion 
and trans-endothelial migration 
(A) Cell proliferation of MDA-231 cells expressing shRNAs targeting MBNL1 or a 
control shRNA was assessed by seeding 2.5 × 104 cells and quantifying the
viable number of cells after five days. N=3. (B) 5x105 MDA-231 cells expressing 
an shRNA targeting MBNL1 or a control shRNA were inject into bilateral 
mammary fat pads of NOD-Scid mice. Once palpable, tumor size was assessed 
by caliper measurements. (C) Cell migration capacity of MDA-231 MBNL1-
knockdown cells compared to control cells was assessed by seeding 5 × 104 cells
in a boyden chamber with 0.8um pores. After 12 hours, the number of cells 
migrated to the basal side of each insert was quantified. N=6-7. (D) Trans-
endothelial migration capacity of MDA-231 cell with MBNL1 knockdown 
compared to control cells was assessed by seeding 5 × 104 cells on a trans-well
insert with 0.3um pores coated with a monolayer of HUVECs. After 12 hours, the 
number of cells migrating through the HUVEC monolayer was quantified by 
counting the number of cells on the bottom side of each insert. N=6. (E) MDA-
231 cells with MBNL1 knockdown or control cells were seeded at 5 × 104 cells
per matrigel-coated insert with 0.8m pores. After 20 hours, the number of cells 
invaded onto the basal side of each insert was quantified. N=12-13. (F) MDA-231 
cells with MBNL1 knockdown and stable overexpression of the MBNL1 open 
reading frame were subjected to transwell invasion assays. N=5. (G) Transwell 
invasion assays were performed using CN34 cells with MBNL1 knockdown or 
control cells. N=5-6. For all, p-values based on a two-way Student’s t-test. Data 
are shown as mean ±SEM .  
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CHAPTER 3: IDENTIFICATION AND ANALYSIS OF DIRECT MBNL1-RNA 
INTERACTIONS 
1. Using HITS-CLIP to identify MBNL1-bound RNAs in breast cancer cells
Given that MBNL1 is an RNA binding protein, and to further investigate the 
molecular mechanism by which MBNL1 mediates metastasis suppression, high 
throughput sequencing-crosslinking immunoprecipitation (HITS-CLIP) was 
performed to identify RNAs that directly interact with MBNL1 in breast cancer 
cells (Figure 3.1A). These MBNL1-interacting RNAs were potential mediators of 
the metastasis suppressive effects of MBNL1, as RNAs bound by MBNL1 may 
also be directly regulated by MBNL1. HITS-CLIP is used to identify endogenous 
RNA targets of RNA binding proteins and uses ultra-violet crosslinking on whole 
cells or tissues to capture in vivo RNA binding protein-RNA interactions 
(Licatalosi et al. 2008). Analysis of the MBNL1 HITS-CLIP sequencing library was 
carried out using the CIMS algorithm, which incorporates information provided by 
the crosslink-induced nucleotide deletions present at the site of RNA-protein 
interaction, a mutation type that is a consequence of the UV radiation used to 
crosslink RNA and proteins in the HITS-CLIP procedure (Zhang et al. 2011). 
Using this program, statistically significant MBNL1-bound regions were identified, 
and FIRE (Elemento et al. 2007), a computational method based on mutual 
information, was used to find any enriched nucleotide motifs in those clusters. 
This analysis found that MBNL1-bound CLIP tag clusters were significantly 
enriched for the GCUU motif (Figure 3.1B), which is in agreement with the YGCY 
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motif previously determined as the optimal MBNL1 binding motif by SELEX 
(Goers et al. 2010). This finding is also in agreement with data from HITS-CLIP 
for MBNL1 in mouse myoblasts, where MBNL1 binding sites were found to be 
enriched for UGC and GCU containing 4mers (Wang et al. 2012). Analysis of the 
relative genic distribution of MBNL1 binding sites revealed that, as expected from 
its known role as a regulator of alternative splicing, the majority of MBNL1 
binding sites occurred in introns. However, MBNL1 interacted with many sites in 
coding and untranslated regions (Figure 3.1C), consistent with recent findings 
from HITS-CLIP studies of MBNL1 in mouse myoblasts (Masuda et al. 2012; 




Figure 3.1 HITS-CLIP of MBNL1 in breast cancer cells 
(A) 32P-labeled RNA-MBNL1 complexes were visualized by autoradiography after 
treatment with low or high concentrations of RNase, and immunoprecipitation 
with anti-MBNL1 or IgG and separation by SDS-PAGE. Western blot for MBNL1 
in equal volumes of lysate used for MBNL1 HITS-CLIP before (input) and after 
(IP sup) immunoprecipitation with MBNL1 antibody or IgG conjugated beads. (B) 
Nucleotide motifs significantly enriched in the MBNL1 bound HITS-CLIP CIMS 
clusters. (C) Pie chart depicting percent of MBNL1 HITS-CLIP clusters mapping 







2. Analysis of MBNL1-regulated alternative splicing events in breast cancer
cells 
MBNL1 has been well characterized as a regulator of alternative splicing 
(Pascual et al. 2006; Wang et al. 2012). Therefore, the effect of MBNL1 depletion 
on alternative splicing in breast cancer cells was examined. To do this, high-
throughput transcriptome sequencing was carried out in MDA-231 cells stably 
expressing a control shRNA or expressing two independent MBNL1-targeting 
shRNAs. The computational tool MISO (Katz et al. 2010), a program that infers 
relative levels of transcript isoforms using RNA sequencing data, was then used 
to identify MBNL1-dependent changes in transcript isoforms in breast cancer 
cells. Alternative exons that had MBNL1-dependent changes in abundance were 
identified by MISO analysis of RNA sequencing data. These were then compared 
with the MBNL1 HITS-CLIP data set to obtain a set of transcripts that had 
MBNL1-dependent differences in exon inclusion and were also bound by MBNL1 
in the HITS-CLIP data, and therefore likely to be directly regulated by MBNL1 
binding. The criteria used to arrive at this set of MBNL1-dependent alternative 
exons was that the event had a bayes factor of ≥10 and a change in the percent 
spliced in exon (ΔΨ) of ≥|0.2| in each of the two independent MBNL1-targeting 
shRNA expressing cell lines compared to the control cell line, as assessed by 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This analysis revealed 21 MBNL1-dependent alternative exons that were in 
transcripts also bound by MBNL1, with 71% of these exons exhibiting inclusion 
and the remainder exhibiting exclusion upon MBNL1 knockdown. Transcripts that 
had MISO predicted MBNL1-dependent changes in exon inclusion and had 
MBNL1 HITS-CLIP binding sites were validated by RT-PCR. Although many of 
the MISO-predicted transcript variants were validated by RT-PCR, several did not 
validate. In these cases, only one of the predicted transcript variants was 
detected by RT-PCR. However, of the genes that had detectable levels of both 
MISO-predicted transcript variants by RT-PCR analysis, there was good 
correlation between the MISO calculated ΔΨ and the ΔΨ assessed by RT-PCR 
(Figure 3.2B). 
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Figure 3.2 MBNL1-dependent skipped exons 
(A) MBNL1 interacts with sites near MBNL1-skipped exons. For the indicated 
transcripts, the skipped exon and its upstream and downstream intron and exon 
are shown, with mapped reads from experimental replicates of MBNL1 HITS-
CLIP. (B) Correlation plots of ΔΨ values calculated by MISO compared to ΔΨ 
values calculated by semi-quantitative RT-PCR for MBNL1-dependent alternative 
exons for genes that had both transcript forms expressed as assessed by RT-
PCR. Shown are separate plots for each independent MBNL1-targeting shRNA 
compared to shCTRL. Pearson correlation coefficient is shown for each plot. 
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This analysis found four genes, FGFR1 (fibroblast growth factor receptor 1), 
SEC31A (SEC31 homolog A), MYL6 (myosin light chain 6), and PICALM 
(phosphatidylinositol binding clathrin assembly protein) that had large (> 30%) 
changes in exon exclusion in MBNL1-knockdown cells compared to control cells 
by both MISO and by RT-PCR analysis, and were bound by MBNL1 (Table 3.1, 
Figure 3.2A, Figure 3.3A). Two of these transcripts, FGFR1 and SEC31A, 
exhibited increased inclusion of a specific exon when MBNL1 was depleted. Two 
others, MYL6 and PICALM, displayed increased exclusion of an exon upon 
MBNL1 depletion. Furthermore, in MDA-231 cells expressing a MBNL1-targeting 
shRNA, overexpression of MBNL1 resulted in the reversion of these splice forms 
(Figure 3.3 A). MBNL1-dependent changes in relative transcript isoform 
abundance were then tested to see if they could affect the transwell invasion 
phenotype observed in MBNL1 depleted cells. In this set of experiments, the 
transcript variant that had an increase in exon inclusion was specifically depleted 
using siRNA. For the transcripts that had an increase in exon inclusion upon 
MBNL1 knockdown (FGFR1, SEC31A), these longer isoforms were 
experimentally depleted using siRNA in MBNL1 knockdown cells. Conversely, 
MYL6 and PICALM had decreased exon inclusion in MBNL1 knockdown cells, 
and therefore their longer isoforms were depleted using siRNA in shCTRL cells. 
The modulation of these transcript isoforms in these cells lines did not have 
significant effect on the transwell invasion capacity of the cells (Figure 3.3B). 
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Figure 3.3 Semi-quantitative RT-PCR analysis of MISO-predicted MBNL1-
dependent alternative splicing events and effect on in vitro invasion 
(A) Semi-quantitative RT-PCR analysis of MBNL1-dependent transcript isoforms 
predicted by MISO in RNA-seq data. Shown are RT-PCR products visualized by 
agarose gel analysis. Percent exon inclusion relative to shCTRL or to MBNL1 
overexpressing cells was calculated using Image J. Cartoons represent the exon 
included (contains the red exon) and the skipped exon forms of each indicated 
transcript, with the DNA length in basepairs indicated for each transcript variant. 
(B) MDA-231 cells expressing shCTRL or sh1MBNL1 were transiently transfected 
with siRNAs targeting the MBNL1-dependent exon of the indicated transcript. 




This result does not exclude the possibility that regulation of alternative splicing 
by MBNL1 contributes to invasion and metastasis. However, in the analysis of 
the group of transcripts identified here, of those that had both direct MBNL1-
dependent differences in transcript isoform expression and the greatest changes 
in isoform expression, none individually affected the invasion capacity of MDA-
231 breast cancer cells. 
CHAPTER 4. MBNL1 REGULATION OF TRANSCRIPT STABILITY AND 
IDENTIFICATION OF MBNL1-STABILIZED METASTASIS SUPPRESSOR 
TRANSCRIPTS  
1. Analysis of MBNL1 effect on global transcript stability
A major type of regulatory activity for RNA binding proteins is control of 
transcript stability. There is some evidence that MBNL1 levels can modulate the 
stability of transcripts in mouse myoblasts (Masuda et al. 2012), but the effect of 
MBNL1 on transcript stability in breast cancer cells has not been reported. 
Therefore, to determine if MBNL1 depletion alters the stability of transcripts to 
which it binds, a transcriptome-wide analysis of RNA stability was conducted. In 
this experiment, breast cancer cells with MBNL1 depleted or control cells, were 
treated with alpha-amanitin to inhibit polymerase II-dependent transcription, and 
RNA was isolated. Relative transcript levels were determined by transcriptomic 
profiling. Relative distribution of MBNL1-bound transcripts in the stability dataset 
was assessed using TEISER (Goodarzi et al. 2014). This analysis showed that 
MBNL1-bound transcripts were enriched among transcripts that had decreased 
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stability upon MBNL1 knockdown (Figure 4.1A). This is consistent with a model 
where MBNL1-bound transcripts are stabilized by MBNL1 binding. 
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Figure 4.1 Identification of MBNL1-stabilized transcripts 
(A) Differential stability of transcripts in MDA-231 MBNL1-depleted compared to 
control cells as assessed by alpha-amanitin treatment and microarray profiling. 
Transcripts were ordered by their log2 fold-change in MBNL1-knockdown cells 
compared to control cells at nine hours after alpha-amanitin treatment normalized 
to pre-alpha-amanitin treated transcript levels. MBNL1-bound transcripts, as 
assessed by HITS-CLIP, were significantly enriched among transcripts 
destabilized by MBNL1-knockdown. (B) Venn diagram of transcripts stabilized 
and bound by MBNL1. (C) qRT-PCR of candidate MBNL1 target transcripts in 
MDA-231 shMBNL1 and shCTRL cells at steady-state. HPRT1 was used as an 
endogenous control. N=3. (D) qRT-PCR of putative MBNL1 target transcripts in 
CN34 shMBNL1 and shCTRL cells at steady-state. HPRT1 was used as an 
endogenous control. 
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Next, the identification of genes directly bound and regulated by MBNL1 
that also mediate MBNL1’s effects on metastasis was carried out. To do this, 
transcripts that were directly bound by MBNL1 in the HITS-CLIP dataset, were 
stabilized by MBNL1 based on the alpha-amanitin analysis, and had reduced 
steady-state abundance upon MBLN1 knockdown, were identified. This analysis 
identified a group of seven transcripts as potential regulators of breast cancer 
metastasis downstream of MBNL1 (Figure 4.1B). The steady-state levels of 
these transcripts were assessed by qRT-PCR in MBNL1-knockdown compared 
to control cells in the MDA-231 and CN34 cancer cell lines. Three of these 
transcripts exhibited reduced steady-state levels upon MBNL1 knockdown in both 
cell lines and using two independent MBNL1-targeting shRNAs: DBNL, TACC1 
and TK1 (Figure 4.1C,D). The reduced stability of these transcripts after alpha-
amanitin treatment and upon MBNL1-depletion in MDA-231 and CN34 cells was 
verified by qRT-PCR (Figure 4.2A,B). The stabilization of these transcripts by 
MBNL1 was also tested using an independent method of transcription inhibition. 
In this assay, dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), an inhibitor of 
CDK9, was used to inhibit transcription. Breast cancer cells were treated with 
DRB and RNA was isolated at various time-points for qRT-PCR analysis. DBNL, 
TACC1, and TK1 transcripts exhibited shorter half-lives in MBNL1-depleted cells 
relative to control cells, while COL6A1, IGFBP4 and VIPR1 transcripts did not 
exhibit significant changes in decay rates in MBNL1-depleted cells relative to 
control cells in this assay (Figure 4.2C). These findings demonstrate that, in 
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breast cancer cells, MBNL1 depletion reduces the stability of a subset of 
transcripts to which it binds. 
Figure 4.2 Validation of MBNL1-dependent transcript stability 
qRT-PCR of putative MBNL1 target transcripts in (A) MDA-231 and (B) CN34 
shMBNL1 and shCTRL cells after nine hours of alpha-amanitin treatment. 18S 
was used as an endogenous control. N=3. (C) qRT-PCR of putative MBNL1 
target transcripts in MDA-231 shMBNL1 and shCTRL cells at times indicated 
after treatment with DRB.  N=3. For all, P-values are from a one-way Student’s t-
test. Data are shown as mean ±S.E.M. 
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2. Effects of DBNL and TACC1 on metastatic invasion in breast cancer 
cells 
MBNL1 depletion leads to the reduced stability and subsequently the 
reduced abundance of DBNL, TACC1 and TK1 transcripts. To test if rescuing the 
expression of these genes in cells depleted of MBNL1 could reverse the 
enhanced metastatic phenotype observed, each of these genes was stably 
overexpressed in MBNL1-depleted cells, using overexpression of mCherry as a 
control gene. These cells were then subjected to in vitro transwell invasion 
assays, and a significant decrease was observed in the invasion capacity of the 
cell lines overexpressing DBNL and TACC1 relative to cells expressing mCherry 
control (Figure 4.3A). However, TK1 over-expression in this context did not 
significantly reduce the invasiveness of MBNL1-depleted cells. As DBNL and 
TACC1 overexpression could both compensate for MBNL1-knockdown in 
transwell invasion assays, elucidating the roles of DBNL and TACC1 in 
repressing invasion and metastasis downstream of MBNL1 was the next step. 
Also, and consistent with these findings, overexpressing DBNL and TACC1 in the 
CN34-Lm1a line, an independent highly metastatic breast cancer cell population, 





Figure 4.3 Effect of DBNL and TACC1 on invasion and metastatic lung 
colonization 
(A) Candidate MBNL1-regulated genes were stably overexpressed in shMBNL1 
MDA-231 cells. mCherry was overexpressed as a control. 5x104 cells were 
seeded in transwell matrigel invasion chambers and the number of cells invading 
to the basal side of the insert was quantified after 20 hours. N=6. (B) CN34-LM1a 
cells stably overexpressing DBNL, TACC1 or mCherry were assessed for 
transwell invasion capacity. N=6. (C) 2x104 MDA-231 cells stably overexpressing 
DBNL, TACC1 or mCherry were injected into the venous circulation of NSG mice. 
Lung colonization was monitored by bioluminescence imaging. N=6. Western blot 
showing levels of DBNL and TACC1 in whole cell lysate from MDA-231 
sh1MBNL1 cells stably overexpressing the indicated factors. Data are shown as 
mean ±SEM. 
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To determine if these genes impacted metastatic lung colonization in vivo, 
breast cancer cell with shRNA-mediated stable MBNL1 knockdown were 
engineered to stably overexpress DBNL, TACC1 or mCherry. These cells were 
injected into the venous circulation of immunodeficient mice. Overexpressing 
DBNL and TACC1 in MBNL1-depleted cells significantly abrogated the enhanced 
metastatic phenotype conferred by MBNL1 depletion (Figure 4.3C). These 
findings demonstrate that overexpression of either DBNL or TACC1 is sufficient 
to repress the metastatic lung colonization of MBNL1-depleted breast cancer 
cells in vivo, as well as to suppress transwell invasion in vitro. 
One commonly used mechanism of regulating mRNA stability is 
alternative poly(A) site choice (APA), which leads to 3’UTR length alterations. 
Both DBNL and TACC1 have extensive binding of MBNL1 in their 3’UTRs, a 
location which could control poly(A) site selection (Figure 4.4A). The length of the 
3’UTRs of DBNL and TACC1 were assessed by qRT-PCR, using primers specific 
to different part of these 3’UTRs. In this analysis, both DBNL and TACC1 3’UTR 
lengths were unchanged upon MBNL1 depletion (Figure 4.4B,C). 
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Figure 4.4 MBNL1 binding on 3’UTRs of DBNL and TACC1 and 3’UTR length 
(A) MBNL1 interacts with the 3’UTRs DBNL and TACC1. The last exon of the 
indicated transcripts are shown with mapped reads from experimental replicates 
of MBNL1 HITS-CLIP. (B) qRT-PCR analysis of DBNL  and (C) TACC1 3’UTR 
length in MDA-231 cells with stable knockdown of MBNL1 or cells expressing a 
control shRNA. 3’UTR primers are numbered as increasingly distal from the stop 




As poly(A) tail length is a major determinant of mRNA stability, the relative 
poly(A) tail lengths of DBNL and TACC1 were assessed. To do this, a method 
employing 3’ tagging of adenylated transcripts and subsequent PCR amplification 
of the poly(A) tail using transcript specific primers, was carried out (Janicke et al. 
2012). This assay revealed no difference in the poly(A) tail length of DBNL and 
TACC1 transcripts upon MBNL1 depletion (Figure 4.5A-D). This result suggested 
that MBNL1 does not regulate the stability of these transcripts through controlling 
their adenylation or deadenylation. These data are consistent with MBNL1 
binding to the 3’UTRs of DBNL and TACC1 and regulating their stability in a 
poly(A) tail length- and APA- independent manner. 
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Figure 4.5 Poly(A) tail length of DBNL and TACC1 transcripts  
The poly(A) tail length of DBNL and TACC1 transcripts was assessed in MDA-
231 shCTRL and MBNL1 knockdown cells as described in methods. The PCR 
products were run on a 2% agarose-TAE gel and stained with ethidium bromide. 
(A,B) DBNL poly(A) tail length using two independent gene-specific primers 
(DBNL-1, DBNL-2). (C,D) TACC1 poly(A) tail length using two independent gene-
specific primers (TACC1-1, TACC1-2).  
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3. Clinical correlation of DBNL and TACC1 in breast cancer outcome
TACC1 expression can be inferred from affymetrix microarray datasets as 
this transcript is represented by an informative probe. Analysis of a large dataset 
comprising 3455 tumor samples representing multiple cohorts revealed a 
significant correlation between TACC1 expression and relapse-free survival in 
breast cancer patients (Figure 4.6A), a finding consistent with TACC1 acting as a 
suppressor of breast cancer metastasis. However, DBNL is not represented by a 
probe on the microarray platform used to analyze these large breast cancer 
datasets. Therefore, to determine whether there exists an association between 
DBNL and breast cancer progression, qRT-PCR was performed on a panel of 
publicly available cDNAs (Origene) generated from breast tumor-derived RNA. 
Consistent with it having a metastasis suppressor role, metastatic stage IV 
tumors expressed significantly lower levels of DBNL relative to stage I and stage 
II tumors (Figure 4.6B). 
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Figure 4.6 Clinical correlation of DBNL and TACC1 expression in breast cancer 
(A) Kaplan-Meier curve showing relapse free survival of breast cancer patients 
with tumors expressing high (red) or low (black) levels of the TACC1 transcript. 
N=3455. (B) Levels of DBNL were assessed by qRT-PCR from RNA obtained 
from a panel of staged breast cancer tumors. Beta-actin was used as an 
endogenous control. N=48. (C) qRT-PCR for MBNL1 and TACC1 in MDA-231 
cells stably expressing two independent TACC1-targeting shRNAs, HPRT1 was 
used as an endogenous control. P-values are based on Student’s t-test unless 
otherwise noted. Data are shown as mean ±SEM.  
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Interestingly, data suggests that MBNL1 is upstream of TACC1 in this regulatory 
relationship, as shRNA-mediated depletion of TACC1 did not affect MBNL1 
transcript levels in MDA-231 cells (Figure 4.6C). However, MBNL1 could 
conceivably be regulated at the transcriptional level by TACC1, as TACC1 has 
been shown to have effects on the transcriptional activity of the retinoic acid 
receptor alpha and thyroid receptor, and also interacts with YEATS4/GAS41, 
which is part of a complex that acetylates histones (Guyot et al. 2010; Lauffart et 
al. 2002). Together, this data is consistent with MBNL1 interacting with TACC1 
and DBNL transcripts to stabilize them, thereby suppressing invasion and 
metastasis of MDA-231 breast cancer cells. DBNL expression is reduced in stage 
IV breast cancer compared to stage I and stage II tumors. TACC1 transcript 
levels are positively correlated with significantly longer relapse-free survival of 
breast cancer patients, suggesting that TACC1 acts as a breast cancer 
metastasis suppressor in human breast cancers. 
4. Effect of secreted proteins on MBNL1-mediated phenotypes
Cancer cells secrete factors that are known to regulate their spread from a 
primary tumor and to promote colonization of distant organs. As MBNL1 
depletion enhanced in vitro invasion and trans-endothelial migration, and both of 
these processes can be modulated by cancer cell-mediated secretion of 
molecules into the extracellular environment, it seemed an intriguing possibility 
that MBNL1 might regulate the expression levels of secreted pro-metastatic 
molecules. A study in mouse myoblasts has also found a role for MBNL protein 
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localization of transcripts that contain a signal peptide sequence (Wang et al. 
2012). To test the possibility that MBNL1 depletion impedes the invasion capacity 
of breast cancer cells through regulation of secreted factors, the invasion 
capacity of cells treated either with media that had been conditioned by MBNL1-
depleted cells or with media that had been conditioned by cells expressing a 
control shRNA was assessed. In this assay, breast cancer cells seeded in 
conditioned media from MBNL1-depleted cells displayed significantly greater 
invasion capacity relative to cells seeded in conditioned media from control cells 
(Figure 4.7A). This finding suggested that factors specifically secreted by 
MBNL1-depleted cells could contribute to the increased cell invasiveness. 
To identify any molecule(s) regulated by MBNL1 that also mediated this 
pro-invasive effect, stable isotope labeling by amino acids in cell culture (SILAC) 
and mass spectrometry (MS) was conducted to identify proteins with different 
levels in media conditioned by control or MBNL1-depleted cells. This experiment 
revealed five proteins with higher abundance in MBNL1-depleted cell conditioned 
media relative to control cell conditioned media. These proteins are CTGF, 
LOXL2, QSOX1, APLP2 and NPC2 (Table 4.1). Three of these factors, CTGF 
(connective tissue growth factor), LOXL2 (lysyl oxidase-like 2), and QSOX1 
(quiescin Q6 sulfhydryl oxidase 1), have been previously implicated in cell 
migration and invasion. LOXL2 and QSOX1 have also been associated with 
breast cancer progression (Ahn et al. 2013; Barker et al. 2011; Chen et al. 2007; 
Katchman et al. 2013). 
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Figure 4.7 Identification of secreted proteins upregulated by MBNL1 depletion 
(A) Conditioned media from MDA-231 cell with MBNL1 knockdown or shCTRL 
cells was used to treat MDA-231 shCTRL cells that were subjected to transwell 
invasion assays. N=5-6. (B) Western blot of conditioned media from MDA-231 
and CN34 cells with MBNL1 knockdown or control cells, all in biological triplicate. 
Bar graphs are quantitation of LOXL2 and QSOX1 signal from the Western blots. 
(C) ELISA for CTGF in conditioned media from MDA-231 cells with MBNL1 
knockdown or control cells. N=3. Data are shown as mean ±S.E.M. 
70 
71 
To validate the up-regulation of these proteins in conditioned media from MBNL1-
knockdown cells compared to control cell conditioned media, Western blotting for 
LOXL2 and QSOX1 was carried out, while an ELISA was used to assay CTGF 
levels (Figure 4.7B,C). 
To assess if these factors could affect the invasion capacity of cells, 
siRNA-mediated knockdown was used to deplete CTGF, LOXL2, and QSOX1 
alone, as well as each of these transcripts in combination with the others. 
Depletion of any one of these factors alone did not affect the invasive capacity of 
breast cancer cells (Figure 4.8A). However, depletion of LOXL2 or QSOX1 in 
combination with depletion of CTGF led to a decrease in the invasion capacity of 
MDA-231 cells (Figure 4.8B). This data is consistent with a role for the secreted 
factors LOXL2, QSOX1 and CTGF in mediating the effect of MBNL1 on breast 
cancer cell invasion. 
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Figure 4.8 Effect of secreted proteins on in vitro invasion  
(A) MDA-231 cells depleted of MBNL1 in combination with CTGF, LOXL2 or 
QSOX1 were subjected to transwell invasion assays. N=5-6. (B) MDA-231 cells 
depleted of MBNL1 in combination with the indicated factors were subjected to 










CHAPTER 5. DISCUSSION 
1. MBNL1 regulation of messenger RNA expression
This study identified MBNL1 as a suppressor of breast cancer 
progression, and discovered that part of this effect is mediated by MBNL1 
regulation of DBNL and TACC1 transcript stability. Interestingly, factors secreted 
by MBNL1-depleted cells were found to moderately enhance cancer cell 
invasion. The mechanism through which these secreted factors are upregulated 
in MBNL1 depleted cells is presently unclear. MBNL1 was also found to directly 
bind and regulate a set of alternatively spliced transcripts in breast cancer cells. 
However, RNAi-mediated modulation of the levels of these transcript variants had 
no significant effect on the in vitro invasion capacity of breast cancer cells. It is 
possible that some of these MBNL1-dependant alternative transcript variants 
contribute to the regulation of metastasis, but may work in concert with each 
other so that modulation of a single splicing event does not have an effect on 
invasion. Therefore, the primary mediator of MBNL1-mediated breast cancer 
metastasis suppression identified in this study is the stabilization of a subset of 
transcripts by MBNL1 binding (Figure 5.1) 
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Figure 5.1 Model of MBNL1 regulation of transcript stability that contributes to 
breast cancer metastasis 
Depiction of MBNL1 binding to the 3’UTRs of DBNL and TACC1 to increase their 
stability and thereby contribute the suppression of breast cancer cell invasion and 
metastasis. 
An open question is the mechanism by which MBNL1 affects the stability 
of mRNAs in breast cancer cells. MBNL1 is known to affect pre-mRNA 
processing by contributing to both alternative exon and alternative poly(A) site 
selection. A recent study reported a regulatory role for MBNL proteins in 
polyadenylation site choice on 3’UTRs in mouse embryonic fibroblasts, thereby 
controlling 3’UTR length (Batra et al. 2014). However, in the current study, there 
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was no observed difference in the 3’UTR length of DBNL and TACC1 transcripts 
upon MBNL1 depletion, as assessed by qRT-PCR. There was also no observed 
change in the length of the poly(A) tails of DBNL and TACC1 transcripts when 
MBNL1 was depleted. These results suggest that APA and poly(A) tail 
lengthening are not mechanisms through which MBNL1 regulates the stability of 
these transcripts, although these regulatory mechanisms may be relevant to the 
control of the stability of other MBNL1-stabilized transcripts. 
One possibility for the mode of MBNL1 regulation of mRNA stability that is 
consistent with this data is MBNL1-dependent localization of mRNAs to stress 
granules and/or P-bodies. MBNL1 has been observed to localize to arsenite-
induced stress granules in HeLa and COS-7 cells (Onishi et al. 2008). Cancer 
cells undergoing the steps necessary for metastatic progression encounter 
stresses that are known to induce stress granule formation, including hypoxia 
and nutrient deprivation. It is possible that a function of MBNL1 in breast cancer 
cells is to localize transcripts to stress granules, where they would be protected 
from decay and then could rapidly resume translation upon removal of the stress. 
Therefore, when MBNL1 is depleted these transcripts would be subjected to 
increased degradation. Similarly, MBNL1 could bind transcripts in P-bodies to 
protect them from decay. This would be a mechanism similar to one observed to 
regulate the poly(A) tail length-independent stability of the HIF1A transcript via 
binding by PAN2 (Bett et al. 2013). In this model for MBNL1 stabilization of 
transcripts, MBNL1 would stabilize a subset of its mRNA targets by localizing 
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them to cytoplasmic RNA granules where they would be protected from decay 
factors. 
2. Regulation of MBNL1 expression and activity
Little is known about the regulation of MBNL1 expression. The most direct 
data addressing this question comes from studies in Drosophila, where it was 
shown that MEF2 (myocyte enhancer factor 2) drives transcription of 
muscleblind, and tissue-specific enhancer elements of muscleblind expression 
were also identified, although these sequences are not conserved in humans 
(Artero et al. 1998; Bargiela et al. 2014). Regulation of MBNL1 levels and activity 
in cancer is a clinically relevant question because of MBNL1’s role in suppressing 
breast cancer metastasis identified in this study. In breast cancer, there are many 
possibilities for regulation of MBNL1 transcript levels. These include decreased 
transcription of the gene through copy number loss at the MBNL1 genetic locus, 
mutation or epigenetic silencing of promoter elements required for transcription of 
MBNL1, or through the loss-of-function of transcription factors that transcribe the 
MBNL1 gene. MBNL1 could also be down-regulated at the mRNA level through 
the alteration of an as yet to be defined cis-regulatory element that controls 
MBNL1 transcript stability, or through levels of a trans-acting factor that controls 
MBNL1 transcript stability. 
The clinical data available for examination in this study only contained 
data for MBNL1 transcript levels, and levels of MBNL1 mRNA do correlate with 
metastasis-free survival of breast cancer patients (Figure 2.3D). However, 
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MBNL1 protein loss-of-function is another formal possibility for down-regulation of 
MBNL1 activity. One mechanism for this would be the mutation of amino acids in 
the MBNL1 protein that affected either its RNA binding ability or its interactions 
with other proteins. Another interesting possibility is regulation of MBNL1 protein 
activity by a toxic RNA gain-of-function mechanism. In this model, cancer cells 
would have unchanged MBNL1 transcript and protein levels, but inhibition of 
MBNL1 activity would occur through sequestration of the MBNL1 protein by an 
RNA containing expanded CUG repeats, in a mechanism similar to that observed 
in myotonic dystrophy. It is plausible that a subset of cancer cells could acquire 
just such a trinucleotide repeat expansion, which would then lead to the 
accumulation of a transcript with a large number of CUG repeats, which could 
then bind MBNL1. Acquisition of expanded CAG trinucleotide repeats at multiple 
loci in breast cancer has been observed (Pizzi et al. 2007). Therefore, it is 
conceivable that such a mechanism could also generate CUG repeat expansions 
in breast cancers. This could lead to the suppression of MBNL1 activity in cancer 
cells and induce acquisition of enhanced metastatic capacity. Interestingly, a 
higher incidence of primary tumor development in individuals affected with 
myotonic dystrophy has been observed, and this increase seems to be specific to 
the disease itself, as unaffected family members do not have an increased 
cancer incidence (Gadalla et al. 2011; Lund et al. 2014; Win et al. 2012). There 
are no reports on the relative incidence of metastatic disease in individuals with 
myotonic dystrophy, but this would be an interesting area for future study. There 
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have also been multiple case reports that have examined samples from 
individuals with myotonic dystrophy who also had cancer of various types, and 
found an expansion of the CUG repeat in the DMPK gene in tumor cells 
compared to normal tissue (Akiyama et al. 2008; Banuls et al. 2004; Jinnai et al. 
1999; Kinoshita et al. 1997; Kinoshita et al. 2002; Ogata et al. 1998; Osanai et al. 
2000). This illustrates the fact that cancers that develop from a wide variety of 
tissues have the ability to generate additional expansions in CUG repeats, which 
could contribute to the down-regulation of MBNL1 and possibly increase the 
metastatic capacity of the cancer cells. 
3. Roles of DBNL and TACC1 in cancer progression
In this study, expression of DBNL and TACC1 counteracted the MBNL1-
depedent effects on cancer cell invasion and metastatic lung colonization. The 
cell biological processes affected by DBNL and TACC1 could conceivably 
mediate these phenotypes. A role for DBNL in suppressing breast cancer 
metastasis has not been previously reported. DBNL (drebrin-like protein) is an F-
actin binding protein and has roles in mammalian development, endocytosis and 
the immune response (Connert et al. 2006; Haag et al. 2012; Hepper et al. 2012; 
Kessels et al. 2000; Larbolette et al. 1999; Schymeinsky et al. 2009). DBNL has 
an N-terminal F-actin binding domain and C-terminal proline rich and SH3 
domains. The DBNL SH3 domain has been reported to interact with factors 
involved in endocytosis, cell motility, and neuronal morphology development 
(Fenster et al. 2003; Hou et al. 2003; Kessels et al. 2001; Pinyol et al. 2007). In a 
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mouse genetic knockout of DBNL, animals have adult onset organ abnormalities, 
including enlarged spleens, dilation and fibrosis of heart chambers, and lung 
emphysema. In adulthood, these animals also develop impaired motor skills, 
which may be due to the observation that they have impaired synaptic vesicle 
recycling of hippocampal boutons (Connert et al. 2006). 
Although there is no reported role for DBNL in cancer progression, a 
recent study showed that DBNL depletion in Src-transformed fibroblasts 
regulates podosome rosette formation and, interestingly, increases cell 
invasiveness (Boateng et al. 2012). Although this effect was observed in 
transformed fibroblasts, this finding is consistent with decreased DBNL levels in 
breast cancer cells enhancing their invasive capacity. Another process relevant 
to metastasis, adhesion to blood vessel walls, has been shown to be affected by 
DBNL in neutrophils. Intriguingly, DBNL has been shown to promote firm 
neutrophil adhesion in vitro under physiologic shear stress conditions and to also 
promote adhesion and extravasation in vivo. Depletion of DBNL resulted in a 
reduced number of integrin-beta-2 clusters in high-affinity conformation. 
Furthermore, DBNL was necessary for neutrophil crawling under flow conditions 
(Hepper et al. 2012; Schymeinsky et al. 2009). Cancer cells go through a process 
similar to this during extravasation. Reduction in the level of DBNL in breast 
cancer cells, if consistent with the function of this protein in neutrophils, would 
decrease adhesion and intraluminal crawling of a cancer cell. This could allow a 
cancer cell to travel farther in the bloodstream and then only adhere to 
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endothelial cells when physically forced to, such as arrest in small capillaries. 
This decrease in adhesion might allow for a cancer cell to spread farther in the 
body. 
TACC1 (transforming acidic coiled-coil containing protein 1) is a member 
of the TACC family, which also contains TACC2 and TACC3. All three of these 
proteins are characterized by the presence of a highly conserved, highly acidic 
200 amino acid long coiled-coil domain at their C-termini (Still et al. 2004). 
Although the down-regulation of TACC1 has been previously reported in breast 
cancer (Conte et al. 2003), the role of this molecule in mediating this process 
remains undefined. TACC1 has been reported to associate with proteins involved 
in diverse cellular processes, including those involved in cell division, specifically 
mitotic spindle dynamics (chTOG/CKAP5, Aurora A, B and C), transcription 
(GAS41/YEATS4, thyroid hormone receptor, retinoid acid receptor alpha, FHL3), 
and RNA processing (LSM7, SNRPG, TDRD7) (Conte et al. 2003; Gabillard et al. 
2011; Guyot et al. 2010; Lauffart et al. 2002; Lauffart et al. 2007). In adult 
humans, transcript levels of TACC1 are highest in the brain, placenta, skeletal 
muscle, spleen, testes, and uterus, and TACC1 levels are higher in the 
developing mouse embryo than in adult mouse tissue (Lauffart et al. 2006). No 
mouse genetic knockout model of TACC1 has been reported. Experiments to 
assess the localization of TACC1 in HeLa cells found that during mitosis, TACC1 
is present at the spindle midzone during anaphase, is localized at the midbody 
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during cytokinesis, while during interphase TACC1 relocalizes to the nucleolus 
(Delaval et al. 2004). 
TACC1 was originally identified as a molecule involved in breast cancer 
because the TACC1 gene is located on 8p11, a chromosomal region commonly 
amplified in breast cancers. Furthermore, it was found that overexpression of 
TACC1 in mouse fibroblasts resulted in cellular transformation and anchorage 
independent growth, suggesting that TACC1 has a role in oncogenesis (Still et al. 
1999). Additionally, ectopic overexpression of TACC1 in a mouse pten 
heterozygous background increased the number of mammary tumors formed 
(Cully et al. 2005). However, in contrast to this, TACC1 mRNA has been shown 
to be down-regulated in breast tumors compared to normal breast tissue, which 
supports a suppressive role for this molecule in breast cancer progression (Conte 
et al. 2003). In agreement with this, analysis of patient data in this current study 
revealed that TACC1 transcript levels are significantly correlated with relapse-
free survival in breast cancer patients (Figure 4.2A). These data can be 
explained if TACC1 acts as both a promoter of tumorigenesis but a suppressor of 
cancer progression. Recently, rare but recurrent fusions of FGFR and TACC 
genes have been reported in glioblastoma multiforme. Fusions of FGFR1-TACC1 
and FGFR3-TACC3 were observed in a small subset of glioblastomas, with the 
tyrosine kinase domain of the FGFR gene fused to the acidic coiled-coil domains 
of the TACC gene. The resulting fusion proteins were found to promote tumor 
growth (Singh et al. 2012). 
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Taken together, the literature on TACC1 is not in agreement on a single 
function for this protein. TACC1 may be involved in MAPK signaling pathways by 
regulating the subcellular localization of phospho-ERK. Through its interactions 
with YEATS4/GAS41, a member of the NuA4 acetyltransferase complex, TACC1 
may also modulate histone acetylation and transcription. It has been implicated 
as a regulator of mitotic exit through its interactions with Aurora B at the midbody 
during cytokinesis, and as a regulator of RNA processing through its interactions 
with LSM7 and SNRPG. The interaction of TACC1 with these RNA processing 
factors is especially intriguing given the role of MBNL1 in RNA processing. LSM7 
is a component of both the LSM1-7 complex and the LSM2-8 complex, which 
mediate cytoplasmic mRNA decapping, and nuclear pre-mRNA splicing and 
decay, respectively (Tharun 2009). SNRPG (small nuclear ribonucleoprotein G) is 
a protein component of the snRNPs that make up the core spliceosome 
machinery. It is therefore possible that downregulation of TACC1 by MBNL1 
results in the dysregulation of splicing and stability of transcripts not directly 
bound by MBNL1. It would also be interesting to test the effect of DBNL and 
TACC1 on modulating the levels of the secreted factors that are upregulated in 
MBNL1-knockdown cells. This might reveal a mechanistic link between MBNL1 
and these downstream secreted factors. 
4. MBNL1-dependent phenotypes and cancer progression
In this study, MBNL1 was found to suppress the invasion and trans-
endothelial migration capacity of breast cancer cells. Both of these processes 
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occur during metastatic progression, and programmed cell invasion is also critical 
during normal development. In fact, MBNL1 has been reported to negatively 
regulate endocardial cell invasion during chick heart development (Vajda et al. 
2009). This illustrates that MBNL1 suppresses cell invasion during specific 
normal developmental processes, and suggests breast cancer cells may be 
commandeering this developmental function of MBNL1 to enhance their invasive 
capacity. Another intriguing finding from the current study is that MBNL1 
depletion results in a significant reduction in cell growth, both in culture and in 
primary tumor growth assays (Figure 2.4A,B). This is consistent with MBNL1 
acting as a promoter of primary tumor growth but a suppressor of metastasis. 
MBNL1 levels are significantly correlated with distant metastasis-free survival in 
breast cancer. Therefore, even if MBNL1 acts to promote primary tumor growth, it 
could be associated with better clinical outcomes in breast cancer because it 
suppresses cancer metastasis to distant organs. This finding is consistent with a 
study that analyzed the outcomes of breast cancer patients that had node 
positive disease and had very small or large primary breast tumors. Patients with 
very small primary tumors had significantly increased breast cancer specific 
mortality compared to those with large tumors (Wo et al. 2011). Therefore, 
MBNL1 may act to suppress cancer cell invasion while simultaneously acting to 
increase growth of the primary tumor. Given this, it is possible that down-
regulation of MBNL1 in small tumors might be an indicator of cancer 
aggressiveness. It is also interesting to note that generally, MBNL1 acts as a 
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promoter of tissue differentiation. Depletion of MBNL1 and MBNL2 leads to a 
reversion to embryonic cell-like splicing patterns, and MBNL1 depletion leads to 
an increased efficiency of induced pluripotent stem cell reprograming (Han et al. 
2013; Lin et al. 2006). MBNL1 is also required for terminal differentiation of red 
blood cells (Cheng et al. 2014). Together, these data are consistent with MBNL1 
acting as a promoter of tissue differentiation. Therefore, it is interesting that in 
breast cancer cells, depletion of MBNL1 leads to an increase in metastatic 
capacity, as plasticity of gene expression can be advantageous during metastatic 
progression. 
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CHAPTER 6. METHODS AND MATERIALS 
Animal Experiments 
All mouse studies were conducted according to a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Rockefeller 
University. For tail-vein colonization assays, 6-8 week old age matched female 
NOD-scid mice were used. Cancer cells were engineered to stably overexpress 
luciferase (Ponomarev et al. 2004), and these cells were injected into the tail vein 
of each mouse. For systemic metastasis assays, 8 week old female athymic 
mice were used, and cancer cells were injected into arterial circulation. The 
location and number of cancer cells was monitored by bioluminescence in living 
animals over times. Statistical significance was based on a one-tailed Mann-
Whitney test. In vivo tumor growth assays were performed by injecting 5x105 
cells mixed with 100ul of matrigel into bilateral mammary fat pats of 7 week old 
female NOD-Scid mice. Tumor volume was assessed by caliper measurements. 
Cell Culture 
All cell lines were maintained at 37°C, 5% CO2. The 293LTV and MDA-
MB-231 and derivative cell lines were cultured in Dulbecco’s modified eagle 
medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, 1mM 
sodium pyruvate, 100 units/mL penicillin, 100 ug/mL streptomycin, and 
amphotericin B (base media and supplements all Life Technologies). HUVECs 
were obtained from ATCC and maintained in EGM-2 media (CC-3162 Lonza) 
supplemented with 2% fetal bovine serum. 
86 
RNAi-Mediated Gene Knockdown 
Lentivirus was produced by transfecting 293LTV cells that had been 
seeded in 6-well plates and allowed to become 60% confluent with 2ug pLKO.1 
shRNA containing vector, 2 ug vector psPAX2 and 1 ug vector pMD2.G.  
TransIT-293T (Mirus Bio) was used for transfection according to the 
manufacturer’s protocol.  Virus was harvested at 48 hours post-transfection and 
passed through a 0.45um syringe filter to remove 293T cells. 
Cancer cells were transduced by incubation with the lentivirus for 6 hours in the 
presence of 8ug/mL polybrene. After transduction, media was changed to normal 
growth media.  Selection was started 48 hours after transduction by adding 
puromycin to a final concentration of 1.5ug/ml.  Cell were kept under selection for 
48 hours. 
For siRNA mediated gene knockdown, cells were seeded at 1.5x105 per 
well in 6-well plates. 20 hours after seeding, cells were transfected with 90 pmol 
of siRNA using lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s instructions. 


















Retroviral and Lentiviral Mediated Protein Overexpression 
Retrovirus was produced by transfecting 293T cells seeded in 6-well 
plates with 2 ug of pBabe containing the ORF of interest, 2 ug Gag/Pol and 1 ug 
VSV-G. Transfection was carried out using transIT-293T (Mirus Bio) according to 
the manufacturer’s protocol.  Virus was harvested 48 hours post-transfection and 
passed through a 0.45um syringe filter to remove cells. For carboxy terminal flag-
tagged MBNL1 overexpression, target cells were transduced by incubation with 
the retrovirus for 6 hours in the presence of 8 ug/mL polybrene. At this time, 
media was changed to normal growth media.  Selection was started 48 hours 
after transduction by adding puromycin to a final concentration of 1.5 ug/mL or 
hygromycin to a final concentration of 350 ug/mL. Puromycin selection was 
88 
maintained for 48 hours, while hygromycin selection was carried out for 11-14 
days. 
Lentivirus was produced by transfecting 293LTV cells seeded in 6-well 
plates with 2 ug pLX304 containing the ORF of interest with a carboxy-terminal 
V5 tag, 2 ug vector psPAX2 and 1 ug vector pMD2.G. TransIT-293T (Mirus Bio) 
was used to transfect the DNA per the manufacturer’s protocol. Virus was 
harvested at 48 hours post-transfection and passed through a 0.45um syringe 
filter to remove 293T cells.  For c-terminal V5-tagged DBNL and TACC1 
overexpression, target cancer cells were transduced by incubation with the 
lentivirus for 6 hours in the presence of 8 ug/mL polybrene.  After transduction, 
media was changed to normal growth media. Selection was started 48 hours 
after transduction by adding puromycin to a final concentration of 1.5 ug/ml. Cells 
were typically kept under selection for 48 hours, or until cells that had not been 
transduced as a control were all dead. 
Transcriptomic Sequencing and Alternative Splicing Analysis 
Whole transcriptome sequencing libraries were constructed using the ScriptSeq 
v2 kit (Epicentre) per the manufacturer’s instructions. The input RNA was isolated 
with a spin column based kit, including an on-column DNase treatment per the 
manufacturer’s instructions (Norgen), and then depleted of rRNA using the Ribo-
Zero kit (Epicentre). The libraries were sequenced at the Rockefeller University 
Genomics Resource center on a HiSeq2000 (Illumina). Reads were first trimmed 
to remove linker sequences and low-quality bases, using cutadapt (v1.2.1). 
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Tophat2 (v2.0.8) was then used to map the reads to the human transcriptome 
(RefSeq transcriptome index, hg19). Cufflinks (v2.0.2) was then used to estimate 
RPKM values and compare shControl and shMBNL1 samples. 
For alternative splicing analysis, mapped reads from each of the two 
MBNL1-targeting shRNA expressing MDA-231 cell lines were compared to the 
shCTRL expressing cell line using MISO (v0.4.9) (Katz et al. 2010), in 
conjunction with the provided annotations for skipped exons, to quantitate 
modulations in alternative splicing events. 
RT-PCR analysis of MISO-predicted transcript variants 
Semi-quantitative real-time PCR was carried out by first isolating RNA and 
synthesizing cDNA. This cDNA was used as the template for PCR to assess the 
relative abundance of transcript isoforms. The PCR products were resolved on 
1.5% or 2% agarose-TAE gels, as determined by the product sizes to be 
separated. The PCR products were then visualized by ethidium bromide staining. 
Quantitation of the bands was done using Image J software (NIH). 
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Table 6.1 Primers used for RT-PCR analysis of MISO-predicted skipped exons 
AKAP8L_SE_F! TGG AAC TTG GAA CTC TGG GA!
AKAP8L_SE_R! ACT CGG GGA TGA TGT TCT GG!
AMOTL1_SE_F! GTG AAT GGG GTT GAT TGT CCG !
AMOTL1_SE_R! AGG AAG TTT GGG GAG TGG AA!
CNOT10_SE_F! GCG AAA GCA GTG AAA CTT GC!
CNOT10_SE_R! GTC TGA TCC TTG GTC CTG CT!
DBNL_SE_F! AGT GAA GGA CCC CAA CTC TG!
DBNL_SE_R! ACG GCA TTG GTC TTC TGG TA!
DCTN1_SE_F! CTG CAA GAA GAT CCG AAG GC!
DCTN1_SE_R! CTT CGA GCT TCA AAC CCA GG!
FGFR1_SE_F! AAG GAG GAT CGA GCT CAC TG!
FGFR1_SE_R! CCA ATA TGG AGC TAC GGG GT!
HDLBP_SE_F! GCT GTG GAG AGG CTA GAA GT!
HDLBP_SE_R! TCT GCC CTT TCT TGC CAA TG!
HEATR2_SE_F! AGG ATT CGA AGA TGA CGC GA!
HEATR2_SE_R! CAC AAA CTC TGG CTC AGG TG!
INCENP_SE_F! CAG TGC AGA GGA ACC AGA TG!
INCENP_SE_R! GAT TCT CCA GGC GCT GC!
MTMR12_SE_F! AAA AGG AGT GGG TCA TGG GT!
MTMR12_SE_R! TCG TTG ATG TTT GAA GCG CA!
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MTX2_SE_F! CTC GTT AAC TGC CGA GAG C!
MTX2_SE_R! GCA TTT TCA GGC CAA GGT TC!
MYL6_SE_F! AGA CAG TGG CCA AGA ACA AG!
MYL6_SE_R! ATT CAC ACA GGG AAA GGC AC!
PICALM_SE_F! ACC AAC AAC CGC TTG GAA TG!
PICALM_SE_R! AAA GGG GTT TGG AGG TCT CA!
PTPRF_SE_F! CGA AGA CCA ACA GCA CAA GG!
PTPRF_SE_R! GCA CGT AGG TGA CCT GGT AG!
RELA_SE_F! AGC ACA GAT ACC ACC AAG AC!
RELA_SE_R! CTT GGA AGG GGT TGT TGT TG!
SEC31A_SE_F! TCC GGG TTT CAT AAT GCA TGG !
SEC31A_SE_R! TGT TCA AAG CTG GAG GGT CA!
TCF3_SE_F! GAC GGG GGT CTC CAC G!
TCF3_SE_R! CAC TGT AGG AGT CGG GAG G!
ZNF512_SE_F! GAT GTC TTC CAG ACT CGG TG!
ZNF512_SE_R! TCG ACA TGA GAA GTA GCA GC!
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Quantitative Real-Time PCR 
To carry out quantitative real time PCR (qRT-PCR), RNA was isolated using a 
total RNA isolation kit, including an on-column DNase treatment (Norgen). 
Synthesis of complementary DNA (cDNA) was carried out using the superscript 
III reverse transcriptase kit (Life Technologies) using an oligodT for priming 
unless otherwise specified. For each cDNA synthesis reaction, an equal mass of 
total RNA reverse transcribed for all samples to be compared. Typically 1-2ug 
per 20ul reaction was used. Synthesis was carried out per the manufactuer’s 
instructions, including an RNase H digestion step. qRT-PCR was carried out in 
technical quadruplicates, using fast syber green master mix (Applied Biosystems) 
and fluorescence was monitored using a 7900HT Fast Real Time instrument 
(Applied Biosystems). Data were analyzed using the delta delta Ct method. 
Endogenous control transcript used for normalization are indicated in each figure. 























Matrigel Invasion Assay 
First, to induce invasiveness, cancer cells were serum-starved in media 
containing 0.2% FBS for 20 hours. Cancer cells with siRNA-induced gene 
knockdown were starved starting at 48 hours post siRNA transfection. The 
starved cancer cells were seeded at 5 x 104 cells per well in matrigel coated 
invasion chambers with 0.8um pore size (BD Biosciences) that had been pre-
equilibrated in 0.2% FBS containing media. The cells were incubated for 20 
hours at 37°C. After the cells had been allowed to invade for 20 hours, the 
matrigel-coated inserts were washed with PBS. Using a q-tip the cells on the top 
94 
side of each insert were scraped off. The inserts were fixed in 4% 
paraformaldehyde for 15 minutes at 37°C, then cut out and mounted onto slides 
using vectashield with DAPI (Vector Laboratories). The number of cells invaded 
through the matrigel was quantified by imaging each insert using an inverted 
fluorescence microscope (Zeiss Axiovert 40 CFL). Five images were taken per 
insert at 10x magnification. ImageJ (NIH) was used to quantify the number of 
invaded cells. 
Trans-Endothelial Migration Assay 
First, monolayers of HUVECs were prepared by seeding 5x104 HUVECs in EGM-
2 media on collagen coated HTS Fluoroblok with 0.3um pores transwell inserts 
(Corning). After monolayer formation, cancer cells that had been serum-starved 
in media containing 0.2% FBS for 20 hours and pulse labeled with cell tracker 
green CMFDA dye (Life Technologies) were seeded on top of the HUVEC 
monolayers at 5 × 104 cancer cells per well, in EGM2 media containing 0.2%
FBS. After 12 hours, the number of cancer cells migrating through the HUVEC 
monolayer was quantified by imaging each insert using an inverted fluorescence 
microscope (Zeiss Axiovert 40 CFL). Four images were taken per insert and 
ImageJ (NIH) was used to quantify the number of cell migrated through the 
HUVEC monolayer. 
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Cell Proliferation Assay 
To assay the effect of MBNL1 knockdown on cell proliferation, 2.5x104 cells were 
seeded in 6-well plates in triplicate. After 5 days, the number of viable cells was 
assessed using trypan blue, which is excluded from living cells. 
Western Blotting 
Whole cell lysate was prepared by washing trypsinized cells 2x with cold PBS, 
resuspending the cell pellet in ice-cold RIPA buffer (25mM Tris-HCl pH 7.6, 
150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with 1x complete 
protease inhibitor cocktail (Roche) and incubating on ice for 20 minutes. The 
lysate was sonicated to shear DNA and then cleared by spinning at 4°C in a 
microcentrifuge at maximum speed for 15 minutes. The total protein 
concentration of the resulting cleared lysate was determined using the BCA 
assay method (Thermo Scientific). Equal amounts of total protein were run on 4-
12% bis-tris NuPAGE gels in MOPS buffer (Life Technologies) under reducing 
conditions. Proteins were transferred to 0.2um PVDF (Millipore) and blocked with 
5% nonfat milk in PBS. Antibodies used in this study include custom made 
polyclonal rabbit anti-MBNL1 (Yenzyme, raised to aa 363-378 of NP_066368), 
anti-flag (Sigma F1804), anti-DBNL (Abcam ab86708) anti-TACC1 (Abcam 
ab187358), anti-QSOX1 (Sigma SAB2700031), anti-LOXL2 (Abcam ab113201)  . 
The blots were incubated with horseradish peroxidase conjugated secondary 
antibodies and developed using the ECL method (Thermo Scientific). 
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High-Throughput Sequencing and Crosslinking Immunoprecipitation 
(HITS-CLIP) 
HITS-CLIP for endogenous MBNL1 was carried out as previously described 
(Jensen and Darnell, 2008), with some modifications, as described in detail 
below. 
Crosslinking of cells 
For each immunoprecipitation, ~5x106 cells were used. MDA-231 cells were 
grown to sub-confluence before crosslinking and harvesting. Cells were rinsed 1x 
with 5 mL cold PBS, the wash aspirated, then an additional 2 mL cold PBS was 
added to just cover the cells. A Biorad genelinker was used to irradiate each 
plate with 400mJ/cm2 UV (254nm) to crosslink RNA to proteins. Plates were 
placed on ice and collected into a falcon tube by scraping. Cells were pelleted at 
2000 rpm for 5 minutes at 4°C, and the PBS aspirated. Cells were resuspended 
in 1mL cold PBS and transferred to a microcentrifuge tube. Cells were pelleted at 
14,000 x g for 30 seconds at 4°C, and the PBS aspirated. The washed, 
crosslinked cell pellets were immediately placed at -80°C. 
Immunoprecipitation 
For each immunoprecipitation,100ul of beads were used. Antibody-conjugated 
beads were prepared by washing protein A dynabeads (Life Technologies) 1x 
with PBS plus 0.02% tween-20, then resuspending beads in PBS plus 0.02% 
tween-20 to 2x the original bead volume. To each 100ul of washed beads, either 
15ug of rabbit IgG (Cell Signaling Technology) or 25ul of anti-MBNL1 antibody 
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(0.6mg/mL)(Yenzyme) was added. The beads and antibodies were rotated at 
room temperature for 30 minutes, then washed 3x with PBS plus 0.02% tween. 
The crosslinked and frozen cell pellets were resuspend in 800uL cold low 
salt wash buffer (1x phosphate buffered saline (PBS), 0.1% Sodium Dodecyl 
Sulfate (SDS), 0.5% sodium deoxycholate, 0.5% IGEPAL CA-630) + 15ul RNasin 
RNase inhibitor (40 units/ul, Promega) + 1x protease inhibitor cocktail (Roche 
EDTA-free protease inhibitor tablets). To digest DNA and reduce viscosity of the 
lysate, 30ul DNaseI RQ1(1 unit/ul, Promega) was added to the lysate and 
incubated at 37°C for 5 minutes at 1000 rpm in a thermomixer. Lysate was 
treated with high and low concentrations of RNase A. For the low RNase 
treatment, RNase A (USB) was added to a final concentration of 30 pg/ul, while 
for the high RNase treatment, RNAse A was added to a final concentration of 
1500 pg/ul. After RNase addition, tubes were incubated at 37°C for 5 minutes, 
then immediately placed on ice. Cell debris was then cleared from the lysate by 
spinning at 16,000xg at 4°C for 20 minutes. The cleared supernatant was then 
pipetted into clean tubes. The antibody-conjugated dynabeads were then added 
to the cleared lysate, and the mixture rotated end-over-end at 4°C for 2 hours. 
After the immunoprecipitation, the beads were collected on a magnet and the 
supernatant removed. The beads were then washed in the following order (all 
washes were ice cold): 2x low salt wash buffer, 2x high salt wash buffer (5X PBS, 
0.1% SDS, 0.5% sodium deoxycholate, 0.5% IGEPAL CA-630), and finally 2x 
PNK buffer (50mM Tris-HCl pH 7.4, 10mM MgCl2, 0.5% IGEPAL CA-630). 
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Labeling and gel resolution of MBNL1-RNA complexes 
In order to visualize the MBNL1 protein-RNA complexes, a radioactively labeled 
RNA oligo was ligated to the immunoprecipitated protein-RNA complexes. To 
prepare the labeled oligo the 3’ RNA linker oligo 5’-GUG UCA GUC ACU UCC 
AGC GG-puromycin was 5’ 32P labeled using T4 PNK (NEB) and γ- 32P ATP 
(Perkin Elmer). The 3’ puromycin is added to the oligo to block unwanted ligation 
products at later steps in the protocol. After end labeling, excess nucleotides 
were removed from the reaction by running it through a G-25 sephadex spin 
column (GE life sciences). To prepare the RNA in the immunoprecipitated 
protein-RNA complexes for ligation, the immunoprecipitation was treated with calf 
alkaline intestinal phosphatase (CIP) (Roche) to dephosphorylate the RNA ends. 
After CIP treatment, the immunoprecipitations were washed in the following 
order, (all washes were ice cold): 1x with PNK buffer, 1x with PNK + EGTA buffer 
(50mM Tris-HCl pH 7.4, 20mM EGTA, 0.5% IGEPAL CA-630), 2x with PNK 
buffer. The 32P-labled RNA oligo was then ligated to the protein complexes by 
adding the following to the beads after removing all of the last wash from the 
previous step: 5ul 10x T4 RNA ligase buffer, 5ul BSA (1mg/mL), 5ul 10mM ATP, 
1.25ul T4 RNA ligase (5 units/ul) (Fermentas), 1.25ul RNasin, 6.25ul 32P-labeled 
3’ linker oligo (7.5 pmol total), H2O to 50ul. Reactions were incubated at 16°C for 
1 hour in a thermomixer with shaking at 1000 rpm for 30 seconds every 15 
minutes. After 1 hour, 48 pmol of the 3’ linker oligo (5’ phosphorylated with cold 
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ATP) was added to the ligation mixture and the mixture was incubated at 16°C 
for 16 hours. 
After ligation of the 3’ linker oligo, the immunoprecipitations were washed 
in the following order (all washes were ice cold): 1x with low salt wash buffer, 1x 
with high salt wash buffer, 3x with PNK buffer. The 5’ ends of the protein-RNA 
complexes were then phosphorylated using T4 PNK, and then washed 3X with 
ice cold PNK buffer. These labeled protein-RNA complexes were then eluted 
from the beads by resuspending the beads in 40ul of 1x NuPAGE loading buffer 
(Life Technologies) and heating at 70 deg C in a thermomixer at 1000 rpm for 10 
minutes. The beads were immediately collected on a magnet, and the eluted 
complexes were run on a 4-12% bis-tris NuPAGE gel (Life Technologies) in 1x 
MOPS running buffer (Life Technologies) at 150 volts in the cold room. The 
complexes were then transferred onto BA-85 nitrocellulose (Whatman) in cold 1x 
NuPAGE transfer buffer with 10% methanol at 100 volts in the cold room. To 
visualize the RNA-protein complexes, the membrane was then exposed to film 
and the film was developed. 
In order to size select the RNA to make the HITS-CLIP library, the bands 
migrating at ~55-70 kDa in the low RNase treated lanes were cut from the 
nitrocellulose. This is because MBNL1 alone migrates at ~40 kDa, and the 
average molecular weight of 50 nucleotide long RNA, the minimum size for 
informative sequencing analysis, is ~15 kDa. The nitrocellulose was cut into 
smaller pieces and treated with proteinase K and then phenol chloroform 
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extracted to digest the protein and isolate the RNA. The aqueous layer was 
precipitated by adding ethanol:isopropanol (1:1), glycoblue, and sodium acetate, 
then incubating overnight at -20°C. The RNA pellet was washed 2x with 75% 
ethanol then air dried, then resuspended in 5.9ul H2O. 
5’ linker ligation, cDNA synthesis and PCR amplification MBNL1 bound RNA 
A 5’ linker RNA oligo was then ligated to the isolated RNA by adding the 
following components to the RNA: 1ul 10x T4 RNA ligase buffer, 1ul BSA 
(0.2mg/mL), 1ul 10mM ATP, 0.1ul T4 RNA ligase, 1ul of the 5’ linker RNA oligo at 
20 pmol/ul (5’-AGGGAGGACGAUGCGG). The ligation mixture was incubated at 
16°C overnight in a PCR tube in a thermocycler. The ligation reaction was then 
treated with DNase to remove any residual DNA. This mixture was then phenol 
chloroform extracted and the RNA recovered from the aqueous layer by 
ethanol:isopropanol precipitation as above. The RNA pellet was washed 2x with 
75% ethanol and then air dried. The RNA pellet was resuspended in 10ul H2O. 
From this RNA, cDNA was synthesized by adding the following to 8ul of 
the resuspended RNA: 2ul DP3 primer at 5pmol/ul (5’-
CCGCTGGAAGTGACTGACAC), 3ul 3mM dNTPs. As a control for DNA 
contamination, a parallel cDNA synthesis without the reverse transcriptase was 
done with the 2ul remaining of the resuspended RNA. The mixtures were 
incubated at 65°C for 5 minutes, then at 4°C for 1 minute. To this, the following 
was added: 1ul 0.1 M DTT, 4ul 5x superscript reverse transcriptase buffer, 1ul 
RNasin, 1ul superscript III (Life Technologies) or 1ul H2O (for the no reverse 
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transcriptase control reactions). The reactions were then incubated at 50°C for 45 
minutes, then 55°C for 15 minutes, then 90°C for 5 minutes, then placed on ice. 
This cDNA was then amplified by PCR using accuprime Pfx supermix (Life 
Technologies and the primer pair: DP5: 5’-AGGGAGGACGATGCGG/ 
DP3: 5’-CCGCTGGAAGTGACTGACAC. The optimal number of cycles was 
determined by running 22-30 cycles of the follow program: 1. 95°C 2 min 2. 95°C 
20 sec 3. 58°C 30 sec 4. 68°C 20 sec. repeat 2-4 for 22-20 cycles 5. 68°C 5 min. 
Formamide loading dye (2x solution: 95% deionized formamide, 5% 100mM 
EDTA pH 7.5, bromophenol blue for tracking) was added to the resulting PCR 
products were run on a 10% TBE-polyacrylamide urea gel and visualized by 
post-staining with SYBR gold (Life Technologies). Amplisize molecular ruler 
(Biorad) was run alongside the PCR products as a size standard. PCR products 
running at ~90-140 basepairs were cut from the gel and the DNA isolated from 
the gel slice using the Qiagen gel extraction kit per instructions for extracting 
DNA fragments from polyacrylamide gels. DNA was eluted from the spin column 
with 30ul EB. 
Next, this eluted DNA was further PCR amplified and Illumina sequencing 
compatible sequences added. To each PCR tube, the following was added: 27ul 
Accuprime Pfx supermix (Life Technologies), 0.5ul 20uM DSFP5 (5'-
AATGATACGGCGACCACCGACTATGGATACTTAGTCAGGGAGGACGATGCG
G), 0.5ul 20uM DSFP3(5'-
CAAGCAGAAGACGGCATACGACCGCTGGAAGTGACTGACAC), 3ul of DNA 
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isolated in previous step. The reactions were then cycled according to the 
following program: 1. 95°C 2 min 2. 95°C 20 sec 3. 58°C 30 sec 4. 68°C 40 sec. 
repeat 2-4 for 6-10 cycles 5. 68°C 5 min. The products were run on a 2% 
metaphor agarose-TBE gel and visualized by ethidium bromide staining. PCR 
products running between 150-170 basepairs were gel extracted using the 
Qiagen gel extraction kit. DNA was eluted from the spin column with 30ul EB. 
Library sequencing and computational analysis 
The biological duplicate MBNL1 HITS-CLIP libraries were sequenced at 
the Rockefeller University Genomics Resource Center on an Illumina HiSeq 2000 
instrument with 50 bp single-end run length. The sequencing reads were first 
trimmed to remove linker sequences and low-quality bases, using cutadapt 
(v1.2.1) with parameters -q 15 and -m 25. The Resulting reads were then aligned 
to the human genome (build hg19) using bowtie2 (v2.1.0). The analytical 
package CIMS (Zhang et al. 2011) was then used to identify CLIP peaks in each 
of the biological replicates (FDR<10%). The peaks from the two replicates were 
then overlapped (intersectBed) to generate a high-confidence list of MBNL1 
binding sites. Sequences were extracted and analyzed for motif discovery using 
ChIPseeqer (Giannopoulou and Elemento 2011). Briefly, a randomized 
background set was generated using a 1st-order Markov Model to control for 
length and dinucleotide frequency in the real binding sites. The resulting 'real' 
and 'scrambled' sequences were then analyzed using FIRE (Elemento et al. 
2007) to identify the best representation of the MBNL1 binding site. 
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Transcript Stability Assays 
For the alpha-amanitin microarray data, MDA-231 MBNL1 knockdown or 
control cells were treated with 10ug/mL alpha-amanitin (Sigma). Nine hours after 
alpha-amanitin addition, RNA was isolated from the cells using a total RNA 
isolation kit with on-column DNase treatment (Norgen). RNA was labeled using 
the TargetAmp nano labeling kit according to the manufactuer’s protocol 
(Epicentre), and hybridized to Illumina beadchip arrays. Lumi package (R) was 
used to normalize and compare Illumina HT12 Beadchip raw signals for 
shControl and sh1MBNL1 samples at 0 and 9 hours post alpha-amanitin 
treatment. The difference between the sh1MBNBL1/shControl logFCs were used 
as a measure of stability. To discretize the input values, transcripts with logFC 
difference of less than -0.1 were labeled as "destabilized". The computational tool 
TEISER, in non-discovery mode, was then used to assess the stability of 
MBNL1-bound transcripts in this dataset (as described in Goodarzi et al. 2014). 
Cells were seeded at 2x105 per well in 6-well plates. 18 hours after 
seeding, 5,6- Dichlorobenzimidazole 1-beta-D-ribofuranoside (DRB)(Sigma) was 
added to the cells to a final concentration of 100μM. RNA was isolated at 0, 2, 4, 
6 and 8 hours after DRB addition using a total RNA isolation kit with on-column 
DNase treatment (Norgen). Relative levels of the transcripts of interest were 
assessed by qRT-PCR, using 18S as the endogenous control. Half-life 
calculations were done using the formula t1/2=ln2/kdecay, where the decay constant 
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was determined by plotting the data on a semilog scale and using non-linear 
regression to find the best fit line (Graphpad Prism). 
Poly(A) Tail Length Assay 
Length of the poly(A) tails was measured as described in (Janicke et al. 2012). 
Total RNA was isolated using a spin-column based total RNA extraction kit, 
including an on-column DNase-treatment step (Norgen). An anchor primer (5’-
GCGAGCTCCGCGGCCGCGTTTTTTTTTTTT ) was annealed to poly(A) 
sequences by mixing the following in a PCR tube: 1ul 100uM ePAT anchor 
primer, 1ug total RNA, H2O to a final volume of 8ul. This was incubated at 80°C 
for 5min, cooled to 25°C, and then Klenow polymerase was used to fill in the 
overhang by adding the following to the mix: 1ul Klenow polyermerase (-exo) 
(5U/ul, NEB), 4ul 5X superscript III buffer, 1ul 0.1M DTT, 1ul 10mM dNTPs, 4ul 
H2O, 1ul RNase out. The mixture was then incubated at 25°C for 1 hour, then the 
Klenow inactivated by incubating at 80°C for 10 min, then cooled to 55°C. While 
holding at 55°C, 1ul superscript III reverse transcriptase (200U/ul, Life 
Technologies) was added and then the mixture incubated at 55°C for another 
hour and the enzyme heat inactivated by incubating at 80°C for 10 min. 
The poly(A) tail length of each transcript of interest was then assessed by using 
this 3’ tagged cDNA as the template from which to PCR amplify the region 
between the anchor primer specific sequence and a sequence 100-300 
nucleotides upstream from the 3’ end of, and specific to, the transcript of interest. 
Oligonucleotides used for poly(A) tail length assay: 
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Universal reverse primer: 5’-GCGCCGGCGCCTCGA 
DBNL-1 forward: 5’-TGTGTGCCTCAACTGATTCTGACTTCAGG 
DBNL-2 forward: 5’-CGGCTCACTCGATGCCTGCAGG 
TACC1-1 forward: 5’-GCGTTGACTACTGCTATCAGGATTGTGTTGTG 
TACC1-2 forward: 5’-GGGTGCCATGAAGTGTGTGAGGAGC 
PCR was carried out by mixing the following: 2.5ul 10x reaction buffer, 0.5ul 
10mM dNTPs, 1ul MgSO4, 1ul 5uM gene specific forward primer (see above), 
1ul 5uM universal reverse primer, 1ul 3’ tagged cDNA (as synthesized in the first 
step), 0.1ul hi fidelity platinum taq (Life Technologies), 17.9ul H2O. The reactions 
were cycled using the following protocol: 1. 94°C 2 min 2. 94°C 15 sec 3. 58°C 
30 sec 4. 68°C 35 sec. repeat 2-4 x 30. 5. 68°C 5 min. The resulting PCR 
products were resolved by running on a 2% agarose-TAE gel and visualized by 
ethidium bromide staining. 
MBNL1, DBNL and TACC1 Expression Correlation with Clinical Outcome 
To test the correlation of MBNL1, MBNL2, MBNL3 and TACC1 expression levels 
with clinical outcome in breast cancer, the kmplot meta data set was used 
(Gyorffy et al. 2010). Expression levels of the genes were divided into high and 
low based on the median expression level, and a censoring threshold of 10 years 
was set. P-values were based on the Mantel-Cox log-rank test. DBNL expression 
correlation with clinical outcome in breast cancer was assessed by qRT-PCR in a 
set of 48 staged breast tumor samples, using beta-actin as an endogenous 
control (Origene, breast cancer panel 3). 
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Conditioned Media Preparation 
Conditioned media for assessment by Western blotting was prepared by seeding 
5x104 cancer cells per well in 24 well plates. After 18 hours, the cells were 
washed twice with PBS, and 0.2mL of serum free DMEM complete media was 
added (DMEM media supplemented with 2mM L-glutamine, 1mM sodium 
pyruvate, 100 units/mL penicillin, 100 ug/mL streptomycin, and amphotericin B). 
After 24 hours, the media was harvested and spun at 5x103 rpm for 10 minutes to 
pellet any cells. The supernatant was removed and equal volumes were assayed 
by Western blotting or ELISA. Extracellular CTGF levels in conditioned media 
from MDA-231 cells with MBNL1 knockdown or control cells were quantified 
using a CTGF ELISA kit (PeproTech). Conditioned media for treatment of cancer 
cells in transwell invasion assays was prepared  in the same manner. 
SILAC-Mass Spectrometry 
Proteins from MDA-231 MBNL1 knockdown cells were isotopically labeled by 
growing in media supplemented with isotopically labeled [13C6]-L-lysine and 
[13C6,15N4]-L-Arginine by passaging cells for ten days in DMEM-flex media 
supplemented with the labeled amino acids along with 10% dialyzed FBS, L-
glutamine, penicillin, streptomycin and amphotericin (Life Technologies).  In 
parallel, MDA-231 cells expressing a control shRNA were passaged identically, 
but in media containing normal lysine and arginine.  To harvest secreted proteins, 
plates were washed twice in PBS, and media containing all of the above 
components except FBS was added.  After 20 hours, the media from the plates 
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was harvested and equal volumes were mixed. The proteins were separated by 
SDS-PAGE, and bands were excised and subjected to mass spectrometry. 
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